SCYNEXIS (SCYX) 10-Q 19 Aug 15 2015 Q2 Quarterly report Financial data

Document and Entity Information

Document and Entity Information - shares	6 Months Ended
	Jun. 30, 2015	Aug. 01, 2015
Document And Entity Information [Abstract]
Document Type	10-Q
Amendment Flag	false
Document Period End Date	Jun. 30, 2015
Document Fiscal Year Focus	2,015
Document Fiscal Period Focus	Q2
Entity Registrant Name	SCYNEXIS INC
Entity Central Index Key	1,178,253
Current Fiscal Year End Date	--12-31
Entity Filer Category	Smaller Reporting Company
Entity Common Stock, Shares Outstanding		13,903,832

Unaudited Condensed Balance She

Unaudited Condensed Balance Sheets - USD ($) $ in Thousands	Jun. 30, 2015	Dec. 31, 2014
Current assets:
Cash and cash equivalents	$ 57,057	$ 32,243
Prepaid expenses and other current assets	1,502	703
Assets held for sale, net	6,086	6,701
Total current assets	64,645	39,647
Other assets	33	25
Total assets	64,678	39,672
Liabilities and stockholders’ equity
Accounts payable	477	426
Accrued expenses	2,835	2,245
Accrued severance and retention costs, current portion	1,408	0
Deferred revenue, current portion	232	257
Liabilities related to assets held for sale	2,099	2,420
Total current liabilities	7,051	5,348
Deferred revenue, net of current portion	764	893
Accrued severance and retention costs, net of current portion	91	0
Total liabilities	$ 7,906	$ 6,241
Commitments and contingencies
Stockholders’ equity:
Common stock	$ 14	$ 8
Additional paid-in capital	190,150	150,934
Accumulated deficit	(133,392)	(117,511)
Total stockholders’ equity	56,772	33,431
Total liabilities and stockholders’ equity	$ 64,678	$ 39,672

Unaudited Condensed Balance Sh3

Unaudited Condensed Balance Sheets (Parenthetical) - $ / shares	Jun. 30, 2015	Dec. 31, 2014
Statement of Financial Position [Abstract]
Common stock, par value	$ 0.001	$ 0.001
Common stock, shares authorized	125,000,000	125,000,000
Common stock, shares issued	13,903,832	8,512,103
Common stock, shares outstanding	13,903,832	8,512,103

Unaudited Condensed Statements

Unaudited Condensed Statements of Operations - USD ($) $ in Thousands	3 Months Ended		6 Months Ended
	Jun. 30, 2015	Jun. 30, 2014	Jun. 30, 2015	Jun. 30, 2014
Income Statement [Abstract]
Total revenue and gross profit	$ 64	$ 65	$ 129	$ 130
Operating expenses:
Research and development	3,282	1,823	7,069	3,143
Selling, general and administrative	3,275	2,255	5,485	3,461
Total operating expenses	6,557	4,078	12,554	6,604
Loss from operations	(6,493)	(4,013)	(12,425)	(6,474)
Other (income) expense:
Amortization of deferred financing costs and debt discount	0	219	0	755
Loss on extinguishment of debt	0	1,389	0	1,389
Interest (income) expense	(1)	5	(2)	49
Derivative fair value adjustment	0	(7,297)	0	(10,080)
Other expense	0	0	0	10
Total other (income) expense	(1)	(5,684)	(2)	(7,877)
(Loss) income from continuing operations	(6,492)	1,671	(12,423)	1,403
Discontinued operations:
(Loss) income from discontinued operations, including $1,350 impairment charge on classification as held for sale for the three and six months ended June 30, 2015	(3,005)	562	(3,458)	1,242
Net (loss) income	(9,497)	2,233	(15,881)	2,645
Deemed dividends, accretion, and allocation of net income to convertible preferred stockholders	0	(262)	0	(1,936)
Net (loss) income attributable to common stockholders - basic	(9,497)	1,971	(15,881)	709
Derivative fair value adjustment	0	(7,297)	0	(10,080)
Net loss attributable to common stockholders - diluted	$ (9,497)	$ (5,326)	$ (15,881)	$ (9,371)
(Loss) income per share attributable to common stockholders - basic
Continuing operations, per basic share	$ (0.53)	$ 0.27	$ (1.20)	$ (0.19)
Discontinued operations, per basic share	(0.25)	0.11	(0.33)	0.45
Earnings Per Share, Basic	(0.78)	0.38	(1.53)	0.26
(Loss) income per share attributable to common stockholders - diluted
Continuing operations, per diluted share	(0.53)	(1.08)	(1.20)	(3.49)
Discontinued operations, per diluted share	(0.25)	0.10	(0.33)	0.41
Earnings Per Share, Diluted	$ (0.78)	$ (0.98)	$ (1.53)	$ (3.08)
Weighted average common shares outstanding:
Basic (shares)	12,249,487	5,181,174	10,393,289	2,771,020
Diluted (shares)	12,249,487	5,454,371	10,393,289	3,044,729

Unaudited Condensed Statements5

Unaudited Condensed Statements of Operations Unaudited Condensed Statement of Operations (Paranthetical) - USD ($) $ in Thousands	3 Months Ended	6 Months Ended
	Jun. 30, 2015	Jun. 30, 2015	Jun. 30, 2014
Income Statement [Abstract]
Impairment on Assets Held for Sale	$ 1,350	$ 1,350	$ 0

Unaudited Condensed Statements6

Unaudited Condensed Statements of Cash Flows - USD ($) $ in Thousands	6 Months Ended
	Jun. 30, 2015	Jun. 30, 2014
Cash flows from operating activities:
Net (loss) income	$ (15,881)	$ 2,645
Adjustments to reconcile net loss to net cash used in operating activities:
Impairment on Assets Held for Sale	1,350	0
Gain on insurance recovery	0	(165)
Loss on extinguishment of debt	0	1,389
Recovery of bad debt	0	(75)
Depreciation	447	615
Stock-based compensation expense	1,115	382
Amortization of deferred financing costs and debt discount	0	755
Change in fair value of derivative liability	0	(10,080)
Changes in deferred rent	(122)	(56)
Changes in operating assets and liabilities:
Accounts receivable and unbilled services	(214)	(394)
Prepaid expenses, other assets, and deferred costs	(1,262)	(351)
Accounts payable and accrued expenses	467	557
Accrued severance and retention cost obligations	1,499	389
Deferred revenue	(218)	321
Net cash used in operating activities	(12,819)	(4,068)
Cash flows from investing activities:
Proceeds from insurance recovery	0	216
Purchases of property and equipment	(527)	(323)
Net cash used in investing activities	(527)	(107)
Cash flows from financing activities:
Proceeds from public offerings	41,400	62,000
Proceeds from sale of preferred stock	0	544
Repayment of debt	0	(15,000)
Payments of deferred offering costs and underwriting discounts and commissions	(3,335)	(6,410)
Proceeds from employee stock purchase plan issuance	95	0
Proceeds from exercise of stock warrants	0	55
Proceeds from exercise of stock options	0	9
Net cash provided by financing activities	38,160	41,198
Net increase in cash and cash equivalents	24,814	37,023
Cash and cash equivalents, beginning of period	32,243	1,402
Cash and cash equivalents, end of period	57,057	38,425
Supplemental cash flow information:
Cash paid for interest	0	49
Noncash financing and investing activities:
Beneficial conversion feature on sale of Series D-2 preferred stock	0	909
Beneficial conversion feature for antidilution adjustment	0	214
Adjustment of preferred stock to redemption value	0	510
Deferred offering costs included in accounts payable and accrued expenses	53	465
Equipment purchases in accounts payable and accrued expenses	20	6
Impairment of fixed asset	0	51
Deferred offering costs reclassified to additional paid-in capital	3,388	4,127
Warrant derivative liability reclassified to additional paid-in capital	0	2,701
Conversion of convertible preferred stock to common stock	$ 0	$ 88,790

Description of Business and Bas

Description of Business and Basis of Preparation	6 Months Ended
	Jun. 30, 2015
Organization, Consolidation and Presentation of Financial Statements [Abstract]
Description of Business and Basis of Preparation	Description of Business and Basis of Preparation Organization SCYNEXIS, Inc. (“SCYNEXIS” or the “Company”) is a Delaware corporation formed on November 4, 1999 . SCYNEXIS is a pharmaceutical company, headquartered in Durham, North Carolina, committed to the discovery, development and commercialization of novel anti-infectives to address significant unmet therapeutic needs. Historically, and through the interim period ended June 30, 2015 , the Company also offered its services in drug discovery and development, primarily in the form of integrated research teams consisting of medicinal, computational, analytical, and process scientists working on a collaborative basis with its customers on research projects. These services were provided by the Company's contract research and development services business (the "Services Business") asset group. On July 21, 2015, the Company completed the sale of the Services Business asset group pursuant to an Asset Purchase Agreement (the "Agreement"), with an effective date of July 17, 2015, with Accuratus Lab Services, Inc. ("Accuratus"), a private-equity backed process chemistry, formulation, manufacturing and analytical development services provider. The material terms of the Services Business sale transaction are described in Note 15. Unaudited Interim Financial Information The accompanying unaudited financial statements and notes have been prepared in accordance with accounting principles generally accepted in the United States, or US GAAP, as contained in the Financial Accounting Standards Board (“FASB”) Accounting Standards Codification (the “Codification” or “ASC”) for interim financial information. In the opinion of management, the interim financial information includes all adjustments of a normal recurring nature necessary for a fair presentation of the results of operations, financial position, and cash flows. The results of operations for the three and six month periods ended June 30, 2015 , are not necessarily indicative of the results for the full year or the results for any future periods. These interim financial statements should be read in conjunction with the financial statements and notes set forth in the Company’s Annual Report on Form 10-K filed with the Securities and Exchange Commission (“SEC") on March 30, 2015. Discontinued Operations As described in Note 14, the Company met the relevant criteria for reporting the Services Business as held for sale and in discontinued operations in the accompanying unaudited interim financial statements as of and for the three and six month periods ended June 30, 2015, and 2014, pursuant to FASB Topic 205-20, Presentation of Financial Statements--Discontinued Operations , and FASB Topic 360, Property, Plant, and Equipment . Use of Estimates The preparation of financial statements in conformity with US GAAP requires the Company to make estimates and assumptions that affect the reported amounts of assets and liabilities and disclosure of contingent assets and liabilities as of the date of the financial statements and the reported amounts of revenues and expenses during the reporting periods. Actual results could differ from those estimates. Significant estimates include: the accounts receivable allowances; the other receivable allowances; the valuation of the related-party deemed contribution; the fair value of the Company’s common stock used to measure stock-based compensation for options granted to employees and nonemployees and to determine the fair value of common stock warrants; the Services Business asset group's fair value less costs to sell, which was used to assess the Services Business asset group for impairment; the fair value of convertible preferred stock; the fair value of the Company’s derivative liability; the estimate of services and effort expended by third-party research and development service providers used to recognize research and development expense; and the estimated useful lives of property and equipment. Reverse Stock-split On March 17, 2014, the Company amended its amended and restated certificate of incorporation to implement a 1-for-4 reverse stock split of its common stock. The reverse stock split did not cause an adjustment to the par value or the authorized shares of the common stock. As a result of the reverse stock split, the Company adjusted the share amounts under its employee incentive plans, outstanding options and common stock warrant agreements with third parties. On April 25, 2014, the Company amended its amended and restated certificate of incorporation to implement an additional 1-for-5.1 reverse stock split of its common stock. The reverse stock split did not cause an adjustment to the par value or the authorized shares of the common stock. As a result of the reverse stock split, the Company further adjusted the share amounts under its employee incentive plans, outstanding options and common stock warrant agreements with third parties. All disclosures of common shares and per common share data in the accompanying interim financial statements and related notes reflect these two reverse stock splits for all periods presented. Initial Public Offering On May 7, 2014, the Company completed an initial public offering (“IPO”) of its common stock. The Company sold an aggregate of 6,200,000 shares of common stock at a public offering price of $10.00 per share. Net proceeds were $54,583 , after deducting underwriting discounts and commissions of $3,290 and offering expenses of $4,127 . Upon the completion of the IPO, all outstanding shares of the Company’s convertible preferred stock were automatically converted into 1,691,884 shares of common stock and certain outstanding warrants were exercised for an additional 275,687 shares of common stock. In connection with the consummation of the IPO, the Company repaid outstanding debt with a principal balance of $15,000 , plus all accrued interest, to the holder of such debt, which was outstanding pursuant to a credit agreement referred to herein as the 2013 Credit Agreement. The significant increase in the shares outstanding beginning in May 2014 has impacted the comparability of the Company's net income (loss) per share calculations between interim 2015 and 2014 periods. April 2015 Follow-on Public Offering On April 28, 2015, the Company completed a follow-on public offering (the "April 2015 Offering") of its common stock. The Company sold an aggregate of 5,376,622 shares of common stock at a public offering price of $7.70 per share. Net proceeds were approximately $38,012 , after deducting underwriting discounts and commissions and offering expenses of approximately $3,388 . The significant increase in the shares outstanding beginning in April 2015 is expected to impact the year-over-year comparability of the Company’s net (loss) income per share calculations for the next twelve months.

Summary of Significant Accounti

Summary of Significant Accounting Policies	6 Months Ended
	Jun. 30, 2015
Accounting Policies [Abstract]
Summary of Significant Accounting Policies	Summary of Significant Accounting Policies Assets Held for Sale The Company generally considers assets to be held for sale (i) when the transaction has been approved by the board of directors or management vested with authority to approve the transaction, (ii) t he assets are available for immediate sale in their present condition, (iii) the Company has initiated an active program to locate a buyer and other actions required to complete the plan to sell the assets, (iv) consummation of the transaction is probable, (v) the assets are being actively marketed for sale at a price that is reasonable in relation to their current fair value, and (vi) the transaction is expected to qualify for recognition as a completed sale, within one year. Following the classification of property and equipment as held for sale, the Company discontinues depreciating the asset and writes down the asset to the lower of carrying value or fair market value, if needed. As described in Note 14, on May 4, 2015, actions taken by the Company's board of directors caused the Company to meet the relevant criteria for reporting the Services Business as held for sale. Concentration of Credit Risk Financial instruments, which potentially expose the Company to concentrations of credit risk consist principally of cash on deposit with a bank, which exceeds the FDIC insurance limits, as well as accounts receivable and unbilled services. Ongoing credit evaluations of the bank and customers' financial condition and independent ratings are reviewed by the Company. Collateralization of deposits has not been required. Deferred Offering Costs Deferred offering costs are expenses directly related to the IPO or the April 2015 Offering. These costs consist of legal, accounting, printing, and filing fees that the Company has capitalized, including fees incurred by the independent registered public accounting firm directly related to the offerings. The IPO deferred offering costs were offset against the IPO proceeds in May 2014 and were reclassified to additional paid-in capital upon completion of the IPO. Deferred costs associated with the April 2015 Offering were offset against the proceeds from the April 2015 Offering and were reclassified to additional paid-in capital upon completion of the April 2015 Offering. Revenue Recognition and Deferred Revenue The Company historically derived the majority of its revenue from providing contract research and development services under fee for service arrangements, which were provided by the Company's Services Business that was sold in July 2015 (see Notes 1 and 15). The Company also has entered into collaboration arrangements in exchange for non-refundable upfront payments and consideration as services are performed. These arrangements include multiple elements, such as the sale of licenses and the provision of services. Under these arrangements, the Company also is entitled to receive development milestone payments and royalties in the form of a designated percentage of product sales. The Company classifies non-refundable upfront payments, milestone payments and royalties received under collaboration and licensing agreements as revenues within its statements of operations because the Company views such activities as being central to its business operations. Revenue is recognized when all of the following conditions are met: (i) persuasive evidence of an arrangement exists, (ii) delivery has occurred or services have been rendered, (iii) fees are fixed or determinable, and (iv) collection of fees is reasonably assured. The Company’s contract research and development services revenue was recognized in the period in which the services were performed. When entering into an arrangement, the Company first determines whether the arrangement includes multiple deliverables and is subject to accounting guidance in ASC subtopic 605-25, Multiple-Element Arrangements . If the Company determines that an arrangement includes multiple elements, it determines whether the arrangement should be divided into separate units of accounting and how the arrangement consideration should be measured and allocated among the separate units of accounting. An element qualifies as a separate unit of accounting when the delivered element has standalone value to the customer. The Company’s arrangements do not include a general right of return relative to delivered elements. Any delivered elements that do not qualify as separate units of accounting are combined with other undelivered elements within the arrangement as a single unit of accounting. If the arrangement constitutes a single combined unit of accounting, the Company determines the revenue recognition method for the combined unit of accounting and recognizes the revenue over the period from inception through the date the last deliverable within the single unit of accounting is delivered. Non-refundable upfront license fees are recorded as deferred revenue and recognized into revenue on a straight-line basis over the estimated period of the Company’s substantive performance obligations. If the Company does not have substantive performance obligations, the Company recognizes non-refundable upfront fees into revenue through the date the deliverable is satisfied. Analyzing the arrangement to identify deliverables requires the use of judgment and each deliverable may be an obligation to deliver services, a right or license to use an asset, or another performance obligation. In arrangements that include license rights and other non-contingent deliverables, such as participation in a steering committee, these deliverables do not have standalone value because the non-contingent deliverables are dependent on the license rights. That is, the non-contingent deliverables would not have value without the license rights, and only the Company can perform the related services. Upfront license rights and non-contingent deliverables, such as participation in a steering committee, do not have standalone value as they are not sold separately and they cannot be resold. In addition, when non-contingent deliverables are sold with upfront license rights, the license rights do not represent the culmination of a separate earnings process. As such, the Company accounts for the license and the non-contingent deliverables as a single combined unit of accounting. In such instances, the license revenue in the form of non-refundable upfront payments is deferred and recognized over the applicable relationship period, which historically has been the estimated period of the Company’s substantive performance obligations or the period the rights granted are in effect. The Company recognizes contingent event-based payments under license agreements when the payments are received. The Company has not received any royalty payments to date. The Company will recognize a milestone payment when earned if it is substantive and the Company has no ongoing performance obligations related to the milestone. A milestone payment is considered substantive if it: 1) is commensurate with either the Company’s performance to achieve the milestone or the enhanced value of the delivered item as a result of a specific outcome from the Company’s performance to achieve the milestone; 2) relates solely to past performance; and 3) is reasonable relative to all of the deliverables and payment terms, including other potential milestone consideration, within the arrangement. Amounts received prior to satisfying all revenue recognition criteria are recorded as deferred revenue in the accompanying balance sheets. The Company’s deferred revenue includes non-refundable upfront payments received under certain licensing and collaboration arrangements that contain substantive performance obligations that the Company is providing over respective defined service or estimated relationship periods. Such non-refundable upfront payments are recognized over these defined service or estimated relationship periods. The Company received a non-refundable upfront payment of $1,500 from R-Pharm in August 2013 which is being recognized over a period of 70 months. The Company recognized revenue in continuing operations from this upfront payment of $64 and $129 for the three and six months ended June 30, 2015 , respectively, and $65 and $130 for the three and six months ended June 30, 2014 , respectively. The Company received a non-refundable upfront payment of $500 in January 2014 under a research services agreement supported by the Company's Services Business, which was being recognized over a period of 48 months. The Company recognized revenue in discontinued operations from this upfront payment of $31 and $63 for the three and six months ended June 30, 2015 , respectively, and $31 and $59 for the three and six months ended June 30, 2014 , respectively. Collaboration Arrangements The Company assesses its contractual arrangements, and presents costs incurred and payments received under contractual arrangements, in accordance with FASB ASC 808, Collaborative Arrangements (Topic 808), when the Company determines that the contractual arrangement includes a joint operating activity, has active participation by both parties, and both parties are subject to significant risks and rewards under the arrangement. When reimbursement payments are due to the Company under a collaborative arrangement within the scope of Topic 808, the Company determines the appropriate classification for each specific reimbursement payment in the statements of operations by considering (i) the nature of the arrangement, (ii) the nature of the Company’s business operations, and (iii) the contractual terms of the arrangement. The Company's August 2013 development, license, and supply agreement with R-Pharm, CJSC (“R-Pharm”), combined with the supplemental arrangement in November 2014, is a collaborative arrangement pursuant to Topic 808 and the Company’s previously described accounting policy. The reimbursements due from R-Pharm for specified research and development costs incurred by the Company are classified as a reduction to research and development expense in the accompanying statements of operations. The reimbursements due to the Company are recorded as a reduction of expense when (i) the reimbursable expenses have been incurred by the Company, (ii) persuasive evidence of a cost reimbursement arrangement exists, (iii) reimbursable costs are fixed or determinable, and (iv) the collection of the reimbursement payment is reasonably assured. The Company recorded receivables for unpaid reimbursement amounts due from R-Pharm of $777 and $226 as of June 30, 2015 and December 31, 2014, respectively, which are presented as other current assets in the accompanying balance sheets. Research and Development Major components of research and development costs include clinical trial activities and services, including related drug formulation, manufacturing, and other development, preclinical studies, cash compensation, stock-based compensation, fees paid to consultants and other entities that conduct certain research and development activities on the Company’s behalf, materials and supplies, legal services, and regulatory compliance. The Company is required to estimate its expenses resulting from its obligations under contracts with clinical research organizations, clinical site agreements, vendors, and consultants in connection with conducting SCY-078 clinical trials and preclinical development. The financial terms of these contracts are subject to negotiations which vary from contract to contract, and may result in payment flows that do not match the periods over which materials or services are provided to the Company under such contracts. The Company’s objective is to reflect the appropriate development and trial expenses in its financial statements by matching those expenses with the period in which the services and efforts are expended. For clinical trials, the Company accounts for these expenses according to the progress of the trial as measured by actual hours expended by CRO personnel, investigator performance or completion of specific tasks, patient progression, or timing of various aspects of the trial. For preclinical development services performed by outside service providers, the Company determines accrual estimates through financial models, taking into account development progress data received from outside service providers and discussions with applicable Company and service provider personnel. Reimbursements of certain research and development costs by parties under collaborative arrangements have been recorded as a reduction of research and development expense presented within the statement of operations. Such reimbursements were recognized under the collaboration arrangement with R-Pharm during the three and six months ended June 30, 2015 . Information about the Company’s research and development expenses and reimbursements due under collaboration arrangements for the three and six months ended June 30, 2015 and 2014, is presented as follows: Three months ended June 30, Six months ended June 30, 2015 2014 2015 2014 Research and development expense, gross $ 3,820 $ 1,823 7,801 3,143 Less: Reimbursement of research and development expense 538 — 732 — Research and development expense, net of reimbursements $ 3,282 $ 1,823 7,069 3,143 Effect of Recent Accounting Pronouncements In April 2014, the FASB issued ASU 2014-08, Reporting Discontinued Operations and Disclosures of Disposals of Components of an Entity , or ASU 2014-08. Under ASU 2014-08, only disposals representing a strategic shift in operations that have a major effect on the Company’s operations and financial results should be presented as discontinued operations. Additionally, ASU 2014-08 requires expanded disclosures about discontinued operations that will provide financial statement users with more information about the assets, liabilities, income, and expenses of discontinued operations. The amendments in ASU 2014-08 are effective for fiscal years, and interim periods within those years, beginning after December 15, 2014. The Company adopted this guidance in the first quarter of 2015 and has applied it in the accompanying interim financial statements for presentation and disclosure of the Services Business as discontinued operations (see Note 14). The Company will also apply, as applicable, the guidance to future dispositions or classifications as held for sale. In May 2014, the FASB issued ASU No. 2014-09, Revenue from Contracts with Customers: Topic 606, or ASU 2014-09. ASU 2014-09 establishes the principles for recognizing revenue and develops a common revenue standard for U.S. GAAP. The standard outlines a single comprehensive model for entities to use in accounting for revenue arising from contracts with customers and supersedes most current revenue recognition guidance, including industry-specific guidance. In applying the new revenue recognition model to contracts with customers, an entity: (1) identifies the contract(s) with a customer; (2) identifies the performance obligations in the contract(s); (3) determines the transaction price; (4) allocates the transaction price to the performance obligations in the contract(s); and (5) recognizes revenue when (or as) the entity satisfies a performance obligation. The accounting standards update applies to all contracts with customers except those that are within the scope of other topics in the FASB Accounting Standards Codification. The accounting standards update also requires significantly expanded quantitative and qualitative disclosures regarding the nature, amount, timing and uncertainty of revenue and cash flows arising from contracts with customers. This guidance is effective for fiscal years and interim periods within those years beginning after December 15, 2016, which is effective for the Company for the year ending December 31, 2017. The FASB delayed in the effective date of the accounting standards update to fiscal years and interim periods within those years beginning on or after December 15, 2017, which is pending approval. The Company is currently evaluating the impact that the implementation of ASU 2014-09 will have on the Company’s financial statements. In August 2014, the FASB issued ASU No. 2014-15, Disclosure of Uncertainties about an Entity’s Ability to Continue as a Going Concern , or ASU 2014-15. ASU 2014-15 will explicitly require management to assess an entity’s ability to continue as a going concern, and to provide related footnote disclosure in certain circumstances. The new standard will be effective for all entities in the first annual period ending after December 15, 2016. Earlier adoption is permitted. The Company is not early adopting ASU 2014-15. The Company is currently evaluating the impact that the implementation of ASU 2014-15 will have on the Company’s financial statements, and the actual impact will be dependent upon the Company’s liquidity and the nature or significance of future events or conditions that exist upon adopting the updated standard. In January 2015, the FASB issued ASU No. 2015-01, Simplifying Income Statement Presentation by Eliminating the Concept of Extraordinary Items, or ASU 2015-01. ASU 2015-01 eliminates from GAAP the concept of extraordinary items. ASU 2015-01 is effective for fiscal years and interim periods beginning after December 15, 2015. Early adoption is permitted. The Company does not expect that the adoption of ASU 2015-01 will have a material impact on its consolidated financial statements. In April 2015, the FASB issued ASU No. 2015-03, Simplifying the Presentation of Debt Issuance Costs , or ASU 2015-03. Under ASU 2015-03, the costs of issuing debt will no longer be recorded as an intangible asset, except when incurred before receipt of the funding from the associated debt liability. Rather, debt issuance costs related to a recognized debt liability will be presented on the balance sheet as a direct deduction from the debt liability, similar to the presentation of debt discounts. The costs will continue to be amortized to interest expense using the effective interest method. ASU 2015-03 is effective for fiscal years and interim periods beginning after December 15, 2015, with early adoption permitted. ASU 2015-03 requires retrospective application to all prior periods presented in the financial statements. The Company does not expect that the adoption of ASU 2015-03 will have a material any impact on its consolidated financial statements. In April 2015, the FASB issued ASU No. 2015-05, Customer’s Accounting for Fees Paid in a Cloud Computing Arrangement” , or ASU 2015-05 . ASU 2015-05 provides guidance to entities about whether a cloud computing arrangement includes a software license. Under ASU 2015-05, if a software cloud computing arrangement contains a software license, entities should account for the license element of the arrangement in a manner consistent with the acquisition of other software licenses. If the arrangement does not contain a software license, entities should account for the arrangement as a service contract. ASU 2015-05 also removes the requirement to analogize to ASC 840-10, to determine the asset acquired in a software licensing arrangement. For public companies, ASU 2015-05 is effective for annual periods, including interim periods within those annual periods, beginning after December 15, 2015, and early adoption is permitted. The Company does not expect that the adoption of ASU 2015-05 will have a material impact on its consolidated financial statements.

Property and Equipment

Property and Equipment	6 Months Ended
	Jun. 30, 2015
Property, Plant and Equipment [Abstract]
Property and Equipment	Property and Equipment Property and equipment consists of the following: June 30, December 31, Equipment $ 9,046 $ 8,552 Furniture and fixtures 375 375 Leasehold improvements 13,212 13,193 Total property and equipment 22,633 22,120 Less accumulated depreciation 17,732 17,285 Property and equipment, net of accumulated depreciation 4,901 4,835 Less impairment charge on classification of property and equipment as assets held for sale 1,350 — Property and equipment, net of accumulated depreciation and impairment charge 3,551 4,835 Property and equipment reclassified to assets held for sale, net (3,551 ) (4,835 ) Property and equipment, net of assets classified as held for sale $ — $ — Depreciation expense was $124 and $447 for the three and six months ended June 30, 2015 , respectively, and $307 and $615 for the three and six months ended June 30, 2014 , respectively. As discussed in Note 14, the Company met the relevant criteria for reporting the Service Business as held for sale on May 4, 2015, and as a result, the Company stopped recording depreciation expense on that date and assessed the property and equipment assets for impairment pursuant to FASB Topic 360, Property, Plant, and Equipment .

Debt Obligations

Debt Obligations	6 Months Ended
	Jun. 30, 2015
Debt Disclosure [Abstract]
Debt Obligations	Debt Obligations Credit Facility Agreement In April 2010, the Company entered into a $15,000 credit facility agreement with HSBC Bank (the “2010 Credit Agreement”). The agreement comprised a $5,000 term loan and a $10,000 revolving credit facility. Borrowings under the 2010 Credit Agreement carried interest at a rate of London InterBank Offered Rate plus 0.95% per annum. The 2010 Credit Agreement required interest-only payments through March 2013 and was guaranteed by a related party that has an investment in the Company. All outstanding borrowings under the agreement were originally due on March 11, 2013. The 2010 Credit Agreement contained no financial covenants. On March 8, 2013, the Company entered into an agreement to amend the 2010 Credit Agreement with HSBC Bank (the “2013 Credit Agreement”). The 2013 Credit Agreement required interest-only payments through December 2014 when all outstanding borrowings were due. Other significant terms of the 2010 Credit Agreement remained the same, which included the guarantee made by a related party that has an investment in the Company. The 2013 Credit Agreement represented a new loan, and the Company determined the value of the extended guarantee under the 2013 Credit Agreement to be $3,930 , which was amortized over the term of the 2013 Credit Agreement. Pursuant to an addendum dated April 29, 2014, upon completion of the IPO on May 7, 2014, the entire outstanding balance of the 2013 Credit Agreement, amounting to $15,000 plus accrued interest, was paid in full using the proceeds from the IPO. The payment on May 7, 2014, released the related party guarantor from all obligations, under and in relation to the 2013 Credit Agreement. The Company recorded a loss on the extinguishment of debt of $1,389 in the three month period ended June 30, 2014, as the remaining deferred financing costs associated with the 2013 Credit Agreement were written off. The Company had no outstanding debt as of June 30, 2015 and as of December 31, 2014. Amortization of deferred financing costs associated with the 2010 Credit Agreement and 2013 Credit Agreement was $0 for both the three and six months ended June 30, 2015 , and $219 and $755 for the three and six months ended June 30, 2014 , respectively. Note and Warrant Purchase Agreements In December 2011, the Company executed a Note and Warrant Purchase Agreement (the “December 2011 Note and Warrant Agreement”) to issue convertible notes in an aggregate amount not to exceed $15,000 . In 2011 and 2012, under the December 2011 Note and Warrant Agreement, the Company issued convertible notes (the “2011-2012 Notes”) with a total principal amount of $11,444 to related parties that held investments in the Company. The 2011-2012 Notes included warrants to purchase 26,000 shares of the Company’s common stock at $0.20 per share. The 2011-2012 Notes were convertible into shares of the Company’s stock under various methods as stipulated in the agreement. In June 2013, the Company executed another Note and Warrant Purchase Agreement (the “June 2013 Note and Warrant Agreement”) with certain existing lenders. Under the June 2013 Note and Warrant Agreement, the lenders agreed to loan to the Company up to $1,500 in exchange for convertible notes (the “June 2013 Notes”). The Company issued June 2013 Notes for an aggregate amount of $899 . In addition, the Company agreed to issue warrants to purchase shares of the Company’s common stock upon the request of a majority of the noteholders. The June 2013 Notes were convertible into shares of the Company’s stock using methods described in the agreement. In addition, the June 2013 Notes included conversion of the entire outstanding principal and interest balance into equity securities upon the closing of any equity financing at the option of the noteholders. On December 11, 2013, the noteholders elected to convert the June 2013 Notes into shares of Series D-2 convertible preferred stock. Also on December 11, 2013, the noteholders elected to convert the 2011-2012 Notes into shares of Series D-1 and Series D-2 convertible preferred stock. There was no outstanding principal or accrued interest associated with the 2011-2012 Notes and June 2013 Notes as of June 30, 2015 and as of December 31, 2014.

Commitments and Contingencies

Commitments and Contingencies	6 Months Ended
	Jun. 30, 2015
Commitments and Contingencies Disclosure [Abstract]
Commitments and Contingencies	Commitments and Contingencies Leases During the period covered by this quarterly report on Form 10-Q, the Company leased its facilities and certain office equipment under long-term non-cancelable operating leases. Rent expense was approximately $219 and $437 for the three and six months ended June 30, 2015 , respectively, and $236 and $467 for the three and six months ended June 30, 2014 , respectively. Future minimum lease payments for all operating leases as of June 30, 2015 are as follows: 2015 $ 550 2016 1,122 2017 1,140 2018 1,161 2019 291 Thereafter — Total $ 4,264 As a condition to the execution of the Asset Purchase Agreement (the "Agreement"), Accuratus is assuming the Company’s post-closing obligation under its facility lease in Durham, North Carolina and the Company is being released from any post-closing liability under the facility operating lease (see Note 14), including the future minimum lease payments included within the table immediately above. The Company and its retained employees will continue to operate from the Durham facility immediately after the closing for a period of up to six months pursuant to a facility license agreement between the Company and Accuratus dated July 17, 2015. At the same time, the Company is in the process of relocating its corporate headquarters and operating activities to Jersey City, New Jersey, where in July 2015 it subleased a premises located at 101 Hudson Street, Jersey City, New Jersey. The material terms of the Jersey City, New Jersey sublease are described in Note 15. License Arrangement with Potential Future Expenditures As of June 30, 2015 , the Company had a license arrangement with Merck Sharp & Dohme Corp., or Merck, that involves potential future expenditures. Under the license arrangement, the Company exclusively licensed from Merck its rights to SCY-078 in the field of human health. SCY-078 is the Company's lead product candidate. Pursuant to the terms of the license agreement, Merck is eligible to receive milestone payments from the Company that could total $19,000 upon occurrence of specific events, including initiation of a phase 3 clinical study, new drug application, and marketing approvals in each of the U.S., major European markets and Japan. In addition, Merck is eligible to receive tiered royalties from the Company based on a percentage of worldwide net sales of SCY-078. The aggregate royalties are mid- to high-single digits. In December 2014, the Company and Merck entered into an amendment to the license agreement that deferred the remittance of a milestone payment due to Merck, such that no amount would be due upon initiation of the first phase 2 clinical trial of a product containing the SCY-078 compound (the "Deferred Milestone"). The amendment also increased, in an amount equal to the Deferred Milestone, the milestone payment that would be due upon initiation of the first Phase 3 clinical trial of a product containing the SCY-078 compound. Except as described above, all other terms and provisions of the license agreement remain in full force and effect. The Company has two additional licensing agreements for other compounds that could require it to make payments of up to $2,300 upon achievement of certain milestones by the Company. Clinical Development Arrangement The Company has entered into, and expects to continue to enter into, contracts in the normal course of business with various third parties who support its clinical trials, preclinical research studies, and other services related to its development activities. The Company's most significant agreement, entered into i n June 2014, is with a third-party clinical research organization to conduct a Phase 2 clinical trial for SCY-078. The scope of the services under the agreement can be modified at any time, and the agreement can be terminated by either party 30 days after receipt of written notice. Other Arrangements The Company entered into an agreement with a third party firm to assist the Company in exploring the divestiture of its Services Business (see Note 14). Pursuant to the terms of the agreement, in the event that the Company was able to complete a divestiture of its contract research and development services business to a third-party, the Company was obligated to pay a success fee to the third party firm for the greater of $500 or 4% of the transaction consideration. As described in Note 15, the Company completed the sale of the Company’s Services Business pursuant to an Asset Purchase Agreement, dated July 17, 2015. The Company paid and expensed an initial retainer of $50 prior to the closing of the Service Business sale transaction. In July 2015, the Company paid the $450 remaining success fee to the third-party firm in connection with the closing of the sale transaction. Compensatory Arrangements with Employees and Officers The Company has entered into certain compensatory arrangements and commitments with employees and officers, the material terms of which are described in Note 13 and Note 15.

Convertible Preferred Stock

Convertible Preferred Stock	6 Months Ended
	Jun. 30, 2015
Temporary Equity Disclosure [Abstract]
Convertible Preferred Stock	Convertible Preferred Stock The Company issued multiple series of convertible preferred stock between 2000 and January 2014. In March 2014, the Company amended its amended and restated certificate of incorporation to require the automatic conversion of all series of convertible preferred stock into common stock upon the completion of a public offering of common stock with gross proceeds of at least $20,000 . In May 2014, upon completion of the IPO, all outstanding shares of convertible preferred stock were converted into an aggregate of 1,691,884 shares of common stock at their respective conversion prices. Warrants Associated with Preferred Stock Issuances In July 2006, the Company issued warrants to purchase 196,923 shares of Series C-1 Convertible Preferred Stock, which converted into the right to purchase 14,033 shares of our common stock in connection with our IPO, however, we refer to these warrants as our Series C-1 Preferred warrants. The Series C-1 Preferred warrants were issued in conjunction with a loan financing agreement with an original exercise price of $3.25 per share of Series C-1 Preferred, which converted into an exercise price of $45.61 per share of common stock in connection with our IPO. These warrants remain outstanding as of June 30, 2015 and will expire on May 7, 2019 , which is the five year anniversary of the Company's IPO. The fair value at the date of grant for these instruments was $459 , which was recorded as a debt discount. The debt discount related to these warrants was fully amortized as of December 31, 2010. The Company determined that the warrants should be recorded as a derivative liability and stated at fair value at each reporting period. The Company recorded other income associated with the fair value adjustment for these warrants of $0 for both the three and six months ended June 30, 2015 , and $0 and $37 for the three and six months ended June 30, 2014 , respectively. On December 11, 2013, the Company entered into an agreement to sell 1,785,712 shares of Series D-2 Convertible Preferred Stock ("Series D-2 Preferred") at $1.40 per share for an aggregate price of $2,500 (the “Series D-2 Purchase Agreement”), less issuance costs of $95 . The Series D-2 Purchase Agreement included warrants to purchase 87,532 shares of the Company’s common stock at $0.20 per share. The fair value of the warrants on the date of issuance was $4,214 , which was recorded as a discount to the Series D-2 Preferred. The fair value of the warrants was $1,714 above the face amount of the Series D-2 Preferred and this excess was expensed to derivative fair value adjustment at issuance. As described in Note 7, the warrants were classified as a derivative liability and were stated at fair value at each reporting period end date prior to being exercised in May 2014 in conjunction with the Company’s IPO. On January 31, 2014, the Company sold 388,641 shares of Series D-2 Preferred to related parties under the Series D-2 Purchase Agreement at $1.40 per share, for an aggregate price of $544 . The sale also included warrants to purchase 19,048 shares of the Company’s common stock at $0.20 per share. The fair value of the warrants on the date of issuance was $906 . The fair value of the warrants was $362 above the face amount of the Series D-2 Preferred and this excess was expensed to derivative fair value adjustment at issuance. As described in Note 7, the warrants were classified as a derivative liability and were stated at fair value at each reporting period end date prior to being exercised in May 2014 in conjunction with the Company’s IPO.

Common Stock

Common Stock	6 Months Ended
	Jun. 30, 2015
Equity [Abstract]
Common Stock	Common Stock Authorized, Issued, and Outstanding Common Shares The Company’s common stock has a par value of $0.001 per share and consists of 125,000,000 authorized shares as of June 30, 2015 , and December 31, 2014 ; 13,903,832 and 8,512,103 shares were issued and outstanding at June 30, 2015 , and December 31, 2014 , respectively. The following table summarizes common stock share activity for the six months ended June 30, 2015 : Shares of Common Stock Balance, December 31, 2014 8,512,103 Common stock issued through April 2015 Offering 5,376,622 Common stock issued through employee stock purchase plan 15,107 Balance, June 30, 2015 13,903,832 Shares Reserved for Future Issuance The Company had reserved shares of common stock for future issuance as follows: As of As of June 30, December 31, Outstanding stock options 1,153,369 615,322 Outstanding Series C-1 Preferred warrants 14,033 14,033 For possible future issuance under 2014 Equity Incentive Plan (Note 8) 618,773 180,610 For possible future issuance under Employee Stock Purchase Plan (Note 8) 52,050 37,746 For possible future issuance under 2015 Inducement Plan (Note 8) 325,000 — Total common shares reserved for future issuance 2,163,225 847,711 Common Stock Warrants The Company had outstanding common stock warrants issued in connection with the Note and Warrant Purchase Agreements (see Note 4) and in connection with certain convertible preferred stock agreements (see Note 6). The December 2011 Note and Warrant Purchase Agreement included warrants to purchase 26,000 shares of the Company’s common stock at $0.20 per share. The warrants could be exercised for shares of common stock, in accordance with their terms. The number of shares of common stock that could be purchased by exercising the warrants would vary based on the event that occurred and would be calculated in accordance with the December 2011 Note and Warrant Purchase Agreements (see Note 4). On December 11, 2013, holders of the June 2013 Notes exercised their rights under the June 2013 Note and Warrant Agreement to receive warrants to purchase shares of the Company’s common stock. As a result of this exercise, the Company issued warrants to purchase 88,987 shares of the Company’s common stock to the holders of the June 2013 Notes at an exercise price of $0.20 per share. These warrants were exercisable until June 28, 2018 , and were exercised in connection with the IPO. On December 11, 2013, in connection with the Series D-2 Convertible Preferred Stock offering, the Company issued warrants to purchase 87,532 shares of the Company’s common stock at an exercise price of $0.20 per share. These warrants were exercisable until December 11, 2018 , and were exercised in connection with the IPO. In addition, as a result of the conversion of the principal and interest outstanding on the 2011-2012 Notes into Series D-1 Preferred and Series D-2 Preferred (see Note 4), in accordance with the amended terms of the agreement, the number of common shares underlying the warrants issued in connection with the 2011-2012 Notes was increased by 54,120 to a total of 80,120 . In connection with the consummation of the IPO in May 2014, the outstanding common stock warrants were exercised at an exercise price of $0.20 per share and the holders received 275,687 shares of common stock. All previously described warrants met the definition of a derivative financial instrument and were accounted for as derivatives. The warrants were stated at fair value at each reporting period end date prior to being exercised in May 2014 in conjunction with the Company’s IPO. The combined fair value of the common stock warrant derivative liabilities, including warrants issued with the sale of Series D-2 Preferred, was $12,200 as of December 31, 2013, and then decreased to $9,998 as of March 31, 2014. The combined fair value of the common stock warrant derivative liabilities continued to decrease in the second quarter of 2014 to $2,701 as of May 2, 2014, and this amount was settled to additional paid in capital on that date as the warrants were exercised in conjunction with the Company's IPO. The fair value adjustment of the long-term derivative liability was recorded as other income in the amounts of $0 for both the three and six months ended June 30, 2015 , respectively, and $7,297 and $10,405 for the three and six months ended June 30, 2014 , respectively.

Stock-based Compensation

Stock-based Compensation	6 Months Ended
	Jun. 30, 2015
Disclosure of Compensation Related Costs, Share-based Payments [Abstract]
Stock-based Compensation	Stock-based Compensation 2009 Stock Option Plan The Company had a share-based compensation plan (the “2009 Stock Option Plan”) under which the Company granted options to purchase shares of common stock to employees, directors, and consultants as either incentive stock options or nonqualified stock options. Incentive stock options could be granted with exercise prices not less than 100% to 110% of the fair market value of the common stock. Options granted under the plan generally vest over three to four years and expire in 10 years from the date of grant. 2014 Equity Incentive Plan In February 2014, the Company’s board of directors adopted the 2014 Equity Incentive Plan, or the 2014 Plan, which was subsequently ratified by its stockholders and became effective on May 2, 2014 (the “Effective Date”). The 2014 Plan is the successor to and continuation of the 2009 Stock Option Plan. As of the Effective Date, no additional awards will be granted under the 2009 Stock Option Plan, but all stock awards granted under the 2009 Stock Option Plan prior to the Effective Date will remain subject to the terms of the 2009 Stock Option Plan. All awards granted on and after the Effective Date will be subject to the terms of the 2014 Plan. The 2014 Plan provides for the grant of the following awards: (i) incentive stock options, (ii) nonstatutory stock options, (iii) stock appreciation rights, (iv) restricted stock awards, (v) restricted stock unit awards, and (vi) other stock awards. Employees, directors, and consultants are eligible to receive awards. Under the 2014 Plan, the aggregate number of shares of common stock that could be issued from and after the Effective Date (the “share reserve”) could not exceed the sum of (i) 257,352 new shares, (ii) the shares that represented the 2009 Stock Option Plan’s available reserve on the Effective Date, and (iii) any returning shares from the 2009 Stock Option Plan. Under the 2014 Plan, the share reserve will automatically increase on January 1 st of each year, for a period of not more than 10 years, commencing on January 1, 2015, and ending on January 1, 2024, in an amount equal to 4.0% of the total number of shares of capital stock outstanding on December 31 st of the preceding calendar year. The board of directors may act prior to January 1 st of a given year to provide that there will be no increase in the share reserve or that the increase will be a lesser number of shares than would otherwise occur. On June 18, 2014, the Company’s board of directors and compensation committee approved an amendment of the 2014 Plan, subject to stockholder approval, to increase the aggregate number of shares of the Company’s common stock that may be issued under the 2014 Plan by an additional 351,653 shares. All other material terms of the 2014 Plan remained unchanged. The Company’s stockholders approved the 2014 Plan amendment on September 11, 2014. Pursuant to the terms of the 2014 Plan, on January 1, 2015, the Company automatically added 340,484 shares to the total number of shares of common stock available for future issuance under the 2014 Plan. On February 25, 2015, the Company's board of directors approved an amendment of the 2014 Plan, subject to stockholder approval, to increase the aggregate number of shares of common stock that may be issued pursuant to awards under the 2014 Plan by an additional 510,726 shares. The Company's stockholders approved the 2014 Plan amendment on June 4, 2015. All other material terms of the 2014 Plan otherwise remain unchanged. April 2015 Stock Option Grants On April 1, 2015, the Company granted options to purchase 425,967 shares of common stock to officers and other key employees, including an award to Dr. Marco Taglietti, the Company's new Chief Executive Officer, to purchase 330,000 shares of the Company's common stock. All options granted on April 1, 2015, have a 10 -year term. For Dr. Taglietti's grant, one-fourth of the shares subject to the option shall vest on the one-year anniversary of the date of grant with the remainder vesting in equal monthly installments for thirty-six months thereafter, provided Dr. Taglietti continues to provide service to the Company. For all other April 1, 2015 officer and key employee grants, the shares subject to the options vest in equal monthly installments for forty-eight months as measured from the date of grant. As of June 30, 2015 , there were 618,773 shares of common stock available for future issuance under the 2014 Plan. Option Amendments During the quarter ended June 30, 2015, the following events resulted in the amendment to terms of outstanding stock option awards: • On June 4, 2015, the Company's board of directors approved an extension to the existing 90 -day post-employment option exercise period to a period ranging from 36 to 48 months for three directors who resigned from the board effective June 4, 2015. The directors held outstanding options to purchase 48,283 shares of the Company's common stock at a weighted average exercise price of $9.01 per share. All outstanding options were fully vested prior to June 4, 2015. • In connection with the Company's sale of its Services Business (Note 13), the Company designed a compensatory plan to promote the retention of services of non-executive employees supporting that business (the "Services Business Plan"). The complete terms of the Service Business Plan are described in Note 13. The Company terminated certain employees in June 2015 (the "June 2015 terminated employees") who became eligible for severance benefits pursuant to the terms of the Services Business Plan. The outstanding stock options held by the June 2015 terminated employees were modified to provide: (i) accelerated vesting of all unvested stock options as of the closing of the sale transaction and (ii) an extension to the existing 90-day post-employment option exercise period, which varies for each employee based upon years of service, with a maximum exercise period of 48 months. As of June 30, 2015, the June 2015 terminated employees held outstanding options to purchase 17,715 shares of the Company's common stock at a weighted average exercise price of $9.64 per share, including aggregate unvested options to purchase 8,331 shares at a weighted average exercise price of $9.64 per share. • As described in Note 13, Charles F. Osborne, Jr., the Company’s former chief financial officer, resigned from the Company effective June 30, 2015. The Company's compensation committee of the board of directors approved the following modifications to Mr. Osborne's outstanding options to purchase the Company's common stock: (i) accelerated vesting of all unvested stock options as of June 30, 2015, and (ii) an extension to the existing 90-day post-employment option exercise period to 36 months. As of June 30, 2015, Mr. Osborne held outstanding options to purchase an aggregate of 74,490 shares of the Company's common stock at a weighted average exercise price of $9.53 per share, including unvested options to purchase 50,814 shares at a weighted average exercise price of $9.49 per share. • As described in Note 13, the Company designed a compensatory plan for its non-executive employees in connection with the relocation of its operations to Jersey City, New Jersey (the "Retention Plan"). Pursuant to the terms of the Retention Plan, all stock options held by non-executive employees eligible under the Retention Plan were modified to provide: (i) accelerated vesting of all unvested stock options as of December 31, 2015, and (ii) an extension to the existing 90-day post-employment option exercise period, which varies for each employee based upon years of service, with a maximum exercise period of 48 months. As of June 30, 2015, the retained employees eligible for participation in the Retention Plan held outstanding options to purchase 121,550 shares of the Company's common stock at a weighted average exercise price of $9.13 per share, including aggregate unvested options to purchase 85,990 shares at a weighted average exercise price of $8.95 per share. The Company determined the additional compensation cost associated with the previously described modifications pursuant to applicable guidance in FASB ASC Topic 718, Compensation—Stock Compensation .The additional compensation cost was determined by calculating the difference between (a) the estimated fair value of each option award immediately prior to the modifications and (b) the estimated fair value of each option award immediately after the modifications. The fair value of each option award immediately prior to and immediately after modification was estimated using the Black-Scholes option-pricing model to determine an incremental fair value, consistent with and in accordance with the Company’s existing accounting policy for stock compensation (see Note 1). Using the Black-Scholes option-pricing model, the weighted-average incremental fair value of outstanding modified option awards was $3.54 per option share. The total additional compensation cost associated with the previously described modifications was determined to be $819 , of which $466 was associated with services previously performed and, therefore, was expensed in the quarter ended June 30, 2015. The remaining additional compensation cost is associated with future service periods and will be recognized as those services are performed. See Note 15 for certain events occurring after June 30, 2015, that resulted in additional amendments to outstanding stock option awards. 2015 Inducement Plan On March 26, 2015, the Company's board of directors adopted the 2015 Inducement Plan, or the 2015 Plan. The 2015 Plan provides for the grant of nonstatutory stock options, stock appreciation rights, restricted stock awards, restricted stock unit awards, and other forms of equity compensation (collectively, stock awards), all of which may be granted to persons not previously employees or directors of the Company, or following a bona fide period of non-employment, as an inducement material to the individuals’ entering into employment with the Company within the meaning of NASDAQ Listing Rule 5635(c)(4). The 2015 Plan has a share reserve covering 450,000 shares of common stock. During the quarter ended June 30, 2015, the Company granted an option to purchase 125,000 shares of the Company's common stock under to the 2015 Inducement Plan. As of June 30, 2015 , there were 325,000 shares of common stock available for future issuance under the 2015 Plan. 2014 Employee Stock Purchase Plan In February 2014, the Company’s board of directors adopted the 2014 Employee Stock Purchase Plan (“ESPP”), which was subsequently ratified by the Company’s stockholders and became effective on May 2, 2014 . The purpose of the ESPP is to provide means by which eligible employees of the Company and of certain designated related corporations may be given an opportunity to purchase shares of the Company’s common stock, and to seek and retain services of new and existing employees and to provide incentives for such persons to exert maximum efforts for the success of the Company. Common stock that may be issued under the ESPP will not exceed 47,794 shares, plus the number of shares of common stock that are automatically added on January 1 st of each year for a period of ten years, commencing on January 1, 2015, and ending on January 1, 2024, in an amount equal to the lesser of (i) 0.8% of the total number of shares of outstanding common stock on December 31 of the preceding calendar year, and (ii) 29,411 shares of common stock. Similar to the 2014 Plan, the board of directors may act prior to January 1 st of a given year to provide that there will be no increase in the share reserve or that the increase will be a lesser number of shares than would otherwise occur. The ESPP is intended to qualify as an “employee stock purchase plan” within the meaning of Section 423 of the Internal Revenue Code. In the quarterly period ended March 31, 2015, the number of shares of common stock available for issuance under the ESPP was automatically increased by 29,411 shares pursuant to the terms of the ESPP and the Company issued 15,107 shares of common stock under the ESPP. There was no activity under the ESPP during the quarterly period ended June 30, 2015. As of June 30, 2015 , there were 52,050 shares of common stock available for future issuance under the ESPP. In connection with the sale of the Services Business, each of the Company’s non-executive officer employees principally providing services to the Services Business has accepted continued employment with the buyer, Accuratus, or has been terminated by July 17, 2015, the effective date of the transaction (see Note 14). As of June 30, 2015, the Company has $59 in employee withholdings under the ESPP that it will return to employees that are no longer employed by the Company because of the sale of the Services Business. These employee withholdings are included in accrued expenses in the accompanying balance sheets. Compensation Cost The compensation cost that has been charged against income for stock awards under the 2009 Stock Option Plan, the 2014 Plan, the 2015 Plan, and the ESPP was $819 and $1,115 for the three and six months ended June 30, 2015 , respectively, and $272 and $382 for the three and six months ended June 30, 2014 , respectively. The total income tax benefit recognized in the statements of operations for share-based compensation arrangements was $0 for the three and six months ended June 30, 2015 and 2014 . Cash received from options exercised was $0 for both the three and six months ended June 30, 2015 , and $4 and $9 for the three and six months ended June 30, 2014 . Stock-based compensation expense related to stock options is included in the following line items in the accompanying statements of operations: Three Months Ended June 30, Six Months Ended June 30, 2015 2014 2015 2014 Research and development 62 100 114 162 Selling, general and administrative 689 135 900 170 Discontinued operations 68 37 101 50 $ 819 $ 272 $ 1,115 $ 382

Income Taxes

Income Taxes	6 Months Ended
	Jun. 30, 2015
Income Tax Disclosure [Abstract]
Income Taxes	Income Taxes The Company did not record a federal or state income tax benefit for the three and six months ended June 30, 2015 and 2014 , due to its conclusion that a full valuation allowance is required against the Company’s deferred tax assets.

Net Loss Per Share

Net Loss Per Share	6 Months Ended
	Jun. 30, 2015
Earnings Per Share [Abstract]
Net Loss Per Share	Net Loss Per Share The Company uses the two-class method to compute net loss per share because the Company has issued securities, other than common stock, that contractually entitle the holders to participate in dividends and earnings of the Company. The two-class method requires earnings for the period to be allocated between common stock and participating securities based upon their respective rights to receive distributed and undistributed earnings. Holders of each series of the Company’s convertible preferred stock were entitled to participate in dividends, when and if declared by the board of directors, that were made to common stockholders, and as a result were considered participating securities. Under the two-class method, for periods with net income, basic net income per common share is computed by dividing the net income attributable to common stockholders by the weighted average number of shares of common stock outstanding during the period. Net income attributable to common stockholders is computed by subtracting from net income the portion of current year earnings that the participating securities would have been entitled to receive pursuant to their dividend rights had all of the year’s earnings been distributed. No such adjustment to earnings is made during periods with a net loss, as the holders of the participating securities have no obligation to fund losses. Diluted net loss per common share is computed under the two-class method by using the weighted average number of shares of common stock outstanding, plus, for periods with net income attributable to common stockholders, the potential dilutive effects of stock options and warrants. In addition, the Company analyzes the potential dilutive effect of the outstanding participating securities when calculating diluted earnings per share. Under the “treasury stock” method, it is assumed that the warrants and options were exercised at the beginning of the period and that the funds obtained from the exercise were used to reacquire the Company’s common stock at the average market price for the period and includes those securities when they are dilutive. Under the “if-converted” method, it is assumed that the outstanding participating securities convert into common stock at the beginning of the period. The Company reports the more dilutive of the approaches as its diluted net income or net loss per share during the period. The following table summarizes the computation of basic and diluted net loss per share attributable to the Company’s common stockholders: Three Months Ended Six Months Ended 2015 2014 2015 2014 Income (loss) attributable to common stock - basic: Income (loss) from continuing operations $ (6,492 ) $ 1,671 $ (12,423 ) $ 1,403 Deemed dividend for beneficial conversion feature on Series D-2 Preferred — — — (909 ) Deemed dividend for antidilution adjustments to convertible preferred stock — — — (214 ) Accretion of convertible preferred stock — — — (510 ) Allocation of net income to convertible preferred stockholders — (262 ) — (303 ) Income (loss) from continuing operations attributable to common stock - basic (6,492 ) 1,409 (12,423 ) (533 ) Income (loss) from discontinued operations attributable to common stock - basic (3,005 ) 562 (3,458 ) 1,242 Net income (loss) attributable to common stock - basic $ (9,497 ) $ 1,971 $ (15,881 ) $ 709 Income (loss) attributable to common stock - diluted: Income (loss) from continuing operations attributable to common stock - basic $ (6,492 ) $ 1,409 $ (12,423 ) $ (533 ) Derivative fair value adjustment — (7,297 ) — (10,080 ) Loss from continuing operations attributable to common stock - diluted (6,492 ) (5,888 ) (12,423 ) (10,613 ) Loss from discontinued operations attributable to common stock - diluted (3,005 ) 562 (3,458 ) 1,242 Net income (loss) attributable to common stock - diluted $ (9,497 ) $ (5,326 ) $ (15,881 ) $ (9,371 ) Weighted-average common shares outstanding: Weighted-average common shares outstanding - basic 12,249,487 5,181,174 10,393,289 2,771,020 Allocation of common stock warrants as participating securities — 273,197 — 273,709 Weighted-average common shares outstanding - diluted 12,249,487 5,454,371 10,393,289 3,044,729 Income (loss) per share - basic: Continuing operations $ (0.53 ) $ 0.27 $ (1.20 ) $ (0.19 ) Discontinued operations (0.25 ) 0.11 (0.33 ) 0.45 Net income (loss) per share - basic $ (0.78 ) $ 0.38 $ (1.53 ) $ 0.26 Income (loss) per share - diluted: Continuing operations $ (0.53 ) $ (1.08 ) $ (1.20 ) $ (3.49 ) Discontinued operations (0.25 ) 0.10 (0.33 ) 0.41 Net income (loss) per share - diluted $ (0.78 ) $ (0.98 ) $ (1.53 ) $ (3.08 ) The following securities, presented on a common stock equivalent basis, have been excluded from the calculation of weighted average common shares outstanding because their effect is anti-dilutive. Three Months Ended Six Months Ended 2015 2014 2015 2014 Convertible preferred stock: Series A Preferred — 6,149 — 6,149 Series B Preferred — 131,685 — 131,685 Series C Preferred — 783,515 — 783,515 Series C-2 Preferred — 173,213 — 173,213 Series D-1 Preferred — 296,773 — 296,773 Series D-2 Preferred — 300,549 — 300,549 Series C-1 Preferred warrants 14,033 14,033 14,033 14,033 Stock options 1,153,369 215,467 1,153,369 215,467 ESPP 7,298 — 7,298 —

Related-Party Transactions

Related-Party Transactions	6 Months Ended
	Jun. 30, 2015
Related Party Transactions [Abstract]
Related-Party Transactions	Related-Party Transactions The Company had transactions with related parties as follows: Three Months Ended June 30, Six Months Ended June 30, 2015 2014 2015 2014 Revenue $ 988 $ 1,822 $ 1,975 $ 3,644 Selling, general and administrative expense $ — $ 500 $ — $ 500 Sanofi owns 100% of a subsidiary that is a customer of the Company's Services Business, which is presented in discontinued operations in the accompanying statements of operations (Note 14). Both Sanofi and the subsidiary have an investment in the Company. The Company’s related-party revenue with the subsidiary composed 27% and 29% total revenue in discontinued operations for the three and six months ended June 30, 2015 , respectively, and 40% and 40% of total revenue in discontinued operations for the three and six months ended June 30, 2014 , respectively. In May 2014, the Company paid a $500 IPO success fee to Burrill Securities, an affiliate of Burrill Biotechnology Capital Fund, L.P., a holder of the Company’s capital stock, pursuant to the engagement letter, as amended. The fee was recognized as general and administrative expense in the accompanying statements of operations.

Fair Value Measurements

Fair Value Measurements	6 Months Ended
	Jun. 30, 2015
Fair Value Disclosures [Abstract]
Fair Value Measurements	Fair Value Measurements The carrying amounts of certain financial instruments, including cash and cash equivalents, accounts receivable, unbilled services, prepaid expenses and other current assets, accounts payable, and accrued expenses approximate their respective fair values due to the short-term nature of such instruments. Assets and Liabilities Measured at Fair Value on a Non-Recurring Basis As discussed in Note 14, the Company met the relevant criteria for reporting the Service Business as held for sale on May 4, 2015 (the "Measurement Date"), and as a result, assessed the asset group for impairment pursuant to FASB Topic 360, Property, Plant, and Equipment . The net carrying value of the Services Business asset group was compared to its fair value as of May 4, 2015. The Company determined that the selling price paid by Accuratus to acquire the Services Business asset group was the best estimate of fair value, which the Company concluded was a Level 2 input. The Company determined that the Services Business asset group's net carrying value exceeded its fair value by $572 on the Measurement Date. The Company also estimated selling costs directly attributable to the sale of the Services Business to be $778 . As a result, the Company recorded a $1,350 impairment charge on property and equipment assets classified as held for sale in the quarterly period ended June 30, 2015. Assets and Liabilities Measured at Fair Value on a Recurring Basis The Company evaluates its financial assets and liabilities subject to fair value measurements on a recurring basis to determine the appropriate level in which to classify them for each reporting period. This determination requires significant judgments to be made. As of June 30, 2015 , and December 31, 2014 , there were no assets or liabilities measured at fair value on a recurring basis. The Company’s derivative liabilities were the only balance sheet amounts that were measured at fair value on a recurring basis. The fair value of these warrant derivatives was based on a valuation of the Company’s common stock. In order to determine the fair value of the Company’s common stock, the Company used a probability-weighted expected return method, or PWERM. Significant inputs for the PWERM included an estimate of the Company’s equity value, a weighted average cost of capital and an estimated probability and timing for each valuation scenario. A reconciliation of the beginning and ending balances for liabilities measured at fair value on a recurring basis using significant unobservable inputs (Level 3) is as follows: Three months ended Six months ended June 30, 2014 June 30, 2014 Balance at beginning of period $ 9,998 $ 12,237 Issuance of warrants — 544 Excess of fair value of warrants over proceeds — 362 Adjustment to fair value (7,297 ) (10,442 ) Reclassification to additional paid-in capital upon exercise of warrants (2,701 ) (2,701 ) Balance at end of period $ — $ —

Compensatory Plan Obligations

Compensatory Plan Obligations	6 Months Ended
	Jun. 30, 2015
Restructuring and Related Activities [Abstract]
Compensatory Plan Obligations	Compensatory Plan Obligations Compensatory Plan with Services Business Employees In connection with the Company's sale of its Services Business, which is more fully described in Note 15, the Company designed a compensatory plan to promote the retention of services of its non-executive employees supporting that business (the "Services Business Plan"). The Company's board of directors adopted, and the Company communicated, the material terms of the Services Business Plan prior to June 30, 2015, to all non-executive employees of the Services Business. The Services Business Plan terms provide for certain cash compensation payments, as well as modifications to the terms of currently outstanding stock options held by such non-executive employees, as more completely described below, upon the successful closing of the sale of the Services Business. The sale closed in July 2015 (see Note 15). The Services Business Plan meets the definition of an exit and disposal activity pursuant to FASB ASC 420-- Exit and Disposal Cost Obligations and all related expenses incurred will be presented in discontinued operations in the statements of operations in the period incurred. The Services Business Plan provided that in the event a non-executive employee of the Services Business was not offered a comparable position by Accuratus, the Company would provide severance payments to such employees. The Company terminated certain employees in June 2015 (the "June 2015 terminated employees") who became eligible for severance benefits totaling approximately $999 pursuant to the terms of the Services Business Plan, of which $908 is included in accrued severance and retention liabilities, current portion, and $91 is included in accrued severance and retention liabilities, net of current portion, in the accompanying balance sheet. The Services Business Plan also provided for certain amendments to the terms of the outstanding stock option awards held by the June 2015 terminated employees, which are described in Note 8. In July 2015, pursuant to the Services Business Plan, the Company paid cash totaling approximately $215 to certain non-executive employees of the Services Business representing an incentive payment upon the closing of the sale of the Services Business. In addition, all non-executive employees of the Services Business will be eligible to receive a cash retention compensation payment from the Company on the earlier of (i) the six month anniversary of the closing of the sale transaction, provided that they remain employed by Accuratus as of such date, or (ii) the date of termination of such employee by Accuratus without good cause. Maximum cash retention compensation payments could total approximately $814 under the Services Business Plan, if all service business employees remain eligible pursuant to the terms of the Services Business Plan. The Company incurred these obligations on the date of the sale of the Services Business in July 2015; therefore, the compensation expense associated with these will be recognized during the quarterly period ended September 30, 2015. The Services Business Plan also includes certain amendments to the terms of the eligible employees' outstanding stock option awards, which are described in Notes 8 and 15. Compensatory Arrangement with Employees of the Company's Continuing Operations In connection with the Company's planned relocation of its continuing operations to Jersey City, New Jersey, the Company designed a compensatory plan to promote the retention of services of non-executive employees supporting its continuing operations (the "Retention Plan"). The Company's board of directors adopted, and the Company communicated, the material terms of the Retention Plan prior to June 30, 2015, to all non-executive employees supporting the Company's continuing operations. The Retention Plan terms provide for certain cash compensation payments and severance payments, as well as modifications to the terms of currently outstanding stock options held by such non-executive employees, as more completely described below. The Company has concluded that the Retention Plan meets the definition of an exit and disposal activity pursuant to FASB ASC 420-- Exit and Disposal Cost Obligations as of June 30, 2015, and all related expenses incurred have been and will be presented in continuing operations in the statements of operations. The Retention Plan provides that non-executive employees are eligible to receive cash bonuses, severance payments and related benefit premiums that could total a maximum of approximately $1,161 , provided that all employees remain employed through December 31, 2015 and are not terminated for cause. The Retention Plan also provides that if the Company and an employee agree upon a services termination date earlier than December 31, 2015 (the "Release Date"), the employee will remain eligible for all terms of the Retention Plan. The Company will accrue this obligation over the remaining future service period required by the employees through the earlier of the Release Date or December 31, 2015. As of June 30, 2015, the Company recognized expense of $165 , which is included in research and development and selling, general, and administrative expenses in the accompanying statement of operations. The corresponding liability is included in accrued severance and retention obligations, current portion, in the accompanying balance sheet. The Retention Plan also includes certain amendments to the terms of the eligible employees' outstanding stock option awards, which are described in Note 8. Compensatory Arrangement with Executive Officer Charles F. Osborne, Jr., the Company’s former chief financial officer, resigned from the Company effective June 30, 2015. The Company's compensation committee of the board of directors approved a compensatory arrangement for Mr. Osborne that provided for certain payments and benefits, including: (i) a cash payment of approximately $ 138 upon his resignation on June 30, 2015; (ii) cash severance payments totaling approximately $179 , which is equal to seven months of Mr. Osborne’s current base salary, paid over seven months commencing with the first payroll period following the resignation date; (iii) a payment representing a contribution Mr. Osborne can use towards continuing COBRA premiums for medical, dental, and vision group health coverage for a period up to seven months after the resignation date; and (iv) certain amendments to the terms of Mr. Osborne's outstanding stock option awards (see Note 8). The cash severance payments and related benefit premiums and payroll taxes totaled approximately $335 as of June 30, 2015, which is included in accrued severance and retention liabilities, current portion, in the accompanying balance sheet.

Discontinued Operations, Assets

Discontinued Operations, Assets Held for Sale, Impairment Charges	6 Months Ended
	Jun. 30, 2015
Discontinued Operations and Disposal Groups [Abstract]
Discontinued Operations, Assets Held for Sale, Impairment Charges	Discontinued Operations, Assets Held for Sale, Impairment Charges As part of the Company's strategic objective to focus its resources on the development of SCY-078, the Company's board of directors directed the Company's management to explore the divestiture of the Company's Services Business. The Company engaged a third-party firm to assist in the evaluation of several divestiture options (i.e., a third-party sale, spin-off, management buy-out or shut-down process). On May 4, 2015, the Company's board of directors completed its evaluation of the various divestiture options and directed management to pursue a plan to sell the Service Business to Accuratus, representing a strategic shift in the Company's operations. The Company met the relevant criteria for reporting the service business as held for sale and in discontinued operations in the accompanying unaudited interim financial statements as of and for the three and six month periods ended June 30, 2015, and 2014, pursuant to FASB Topic 205-20, Presentation of Financial Statements--Discontinued Operations , and FASB Topic 360, Property, Plant, and Equipment . The Company assessed the Services Business net asset group for impairment pursuant to FASB Topic 360 and recorded a $1,350 impairment charge on classification of property and equipment assets as held for sale in the quarterly period ended June 30, 2015. The fair value measurement used to determine the impairment charge has been described in Note 12. On July 21, 2015, the Company completed the sale of the Services Business to Accuratus pursuant to the Agreement, with an effective date of July 17, 2015 (see Note 15). As a condition to the execution of the Agreement, Accuratus assumed the Company’s post-closing obligation under its facility lease in Durham, North Carolina (see Note 5). The Company and its retained employees will continue to operate from the Durham facility immediately after the closing for a period of up to six months pursuant to a facility license agreement. In addition, under a Transition Services Agreement, Accuratus will provide accounting, IT, payroll, personnel and human resources support, and equity compensation plan administration support services to the Company at rates ranging from one hundred to two hundred dollars per hour for a period of time not to extend beyond December 31, 2015. The Company and Accuratus also entered into a Commitment to Services Agreement (the "Services Agreement") pursuant to which Accuratus will provide the Company with certain contract research and development services for 18 months (the "Initial Term") following the closing of the sale of the Services Business for a minimum purchase obligation of at least $3,300 due from the Company over the Initial Term of the Services Agreement. The purpose of the Services Agreement is to replace services that were previously provided internally by employees of the Company prior to the sale of the Services Business. The employees performing these services became employees of Accuratus in connection with this sale transaction. The following table presents a reconciliation of the carrying amounts of assets and liabilities of the Services Business to assets held for sale, net in the balance sheets: June 30, 2015 December 31, 2014 Carrying amounts of assets included as part of discontinued operations: Accounts and unbilled receivables, net $ 1,715 $ 1,501 Prepaid expenses and other current assets 761 289 Property and equipment, net 4,901 4,835 Other assets 59 76 Disposal loss recognized on classification as held for sale (1,350 ) — Assets held for sale, net $ 6,086 $ 6,701 Carrying amounts of liabilities included as part of discontinued operations: Accounts payable and accrued expenses $ 546 $ 681 Deferred revenue 381 445 Deferred rent 1,172 1,294 Liabilities related to assets held for sale $ 2,099 $ 2,420 The following table presents revenue, (expenses), gains, and (losses) attributable to discontinued operations: Three months ended June 30, Six months ended June 30, 2015 2014 2015 2014 Major line items constituting income (loss) of discontinued operations: Total revenue $ 3,617 $ 4,577 $ 6,849 $ 9,217 Cost of revenue (3,599 ) (4,180 ) (6,830 ) (8,140 ) Research and development (422 ) — (853 ) — Selling, general and administrative (198 ) — (221 ) — Gain on insurance recovery — 165 — 165 Severance and exit costs (Note 13) (1,053 ) — (1,053 ) — Impairment charge from classification of assets as held for sale (1,350 ) — (1,350 ) — Income (loss) from discontinued operations $ (3,005 ) $ 562 $ (3,458 ) $ 1,242 The following table presents depreciation, capital expenditures, and significant operating and investing non-cash items related to the discontinued operations: Six months ended June 30, 2015 2014 Depreciation expense $ 391 $ 562 Purchases of property and equipment (527 ) (323 ) Stock-based compensation 101 50 Changes in deferred rent (122 ) (56 ) Equipment purchases in accounts payable and accrued expenses 20 6

Subsequent Events

Subsequent Events	6 Months Ended
	Jun. 30, 2015
Subsequent Events [Abstract]
Subsequent Events	Subsequent Events Sale of the Services Business On July 21, 2015, the Company completed the sale of the Company’s Services Business pursuant to an Asset Purchase Agreement, with an effective date of July 17, 2015, with Accuratus Lab Services, Inc. a private-equity backed process chemistry, formulation, manufacturing and analytical development services provider, for an aggregate purchase price of $3,875 , subject to a working capital adjustment of $824 , which reduced the proceeds at closing. In addition, a portion of the consideration payable at closing equal to $500 was withheld and is subject to an escrow for a period of 12 months from the date of closing to satisfy indemnification obligations of the Company in connection with breaches of any representation and warranties and other customary obligations under the terms of the Agreement. The net cash consideration received by us upon closing in July 2015 was $2,549 , after adjusting for the items described above and a nominal escrow fee. As a condition to the execution of the Agreement, Accuratus is assuming the Company’s post-closing obligation under its facility lease in Durham, North Carolina (see Note 5). The Company and its retained employees will continue to operate from the Durham facility immediately after the closing for a period of up to six months pursuant to a facility license and a transition services agreement. In addition, under a Transition Services Agreement, Accuratus will provide accounting, IT, payroll, personnel and human resources support, and equity compensation plan administration support services to the Company at rates ranging from one hundred to two hundred dollars per hour for a period of time not to extend beyond December 31, 2015. In connection with the sale of the Services Business, each of the Company’s non-executive officer employees principally providing services to the Services Business have either accepted continued employment with Accuratus or has terminated in connection with the transaction contemplated by the Agreement. Pursuant to the Services Business Plan described in Note 13, the Company paid cash totaling approximately $215 to certain non-executive employees of the Services Business as an incentive payment upon the closing of the sale transaction in July 2015. In addition, all non-executive employees of the Services Business will be eligible to receive a cash retention compensation payment from the Company on the earlier of (i) the six month anniversary of the closing of the sale transaction, provided that they remain employed by Accuratus as of such date, or (ii) the date of termination of such employee by Accuratus without good cause. Maximum cash retention compensation payments could total approximately $814 under the Services Business Plan, if all service business employees remain eligible pursuant to the terms of the Services Business Plan. The Company incurred these obligations on the date of the sale of the Services Business in July 2015; therefore, the compensation expense associated with these will be recognized during the quarterly period ended September 30, 2015. In addition, the stock options held by each non-executive employee of the Services Business were modified immediately prior to the closing of the sale transaction in July 2015 to provide: (i) accelerated vesting of all unvested stock options as of the closing of the sale transaction and (ii) an extension to the existing 90-day post-employment option exercise period, which varies for each employee based upon years of service, with a maximum exercise period of 48 months. As of June 30, 2015, the non-executive employees of the Services Business held outstanding options to purchase 37,517 shares of the Company's common stock at a weighted average exercise price of $9.62 per share, including unvested options to purchase 23,052 shares at a weighted average exercise price of $9.61 per share. The incremental stock compensation expense associated with these modifications will be recognized during the quarterly period ended September 30, 2015. The Company entered into an agreement with a third party firm to assist the Company in exploring the divestiture of its Services Business. Pursuant to the terms of the agreement, in the event that the Company was able to complete a divestiture of the Services Business to a third-party, the Company was obligated to pay a success fee to the third party firm for the greater of $500 or 4% of the transaction consideration. The Company paid and expensed an initial retainer prior to the closing of the Service Business sale transaction, and then paid a $450 remaining success fee due to the third party firm in July 2015 in connection with the closing of the sale transaction. Commitment to Services Agreement On July 17, 2015, the Company and Accuratus also entered into the Services Agreement pursuant to which Accuratus will provide the Company with certain contract research and development services for 18 months (the "Initial Term") following the closing of the sale of the Services Business for a minimum purchase obligation on the part of the Company of at least $3,300 over the Initial Term of the Services Agreement. The purpose of the Services Agreement is to replace services that were previously provided internally by employees of the Company prior to the sale of the Services Business. The employees performing these services became employees of Accuratus in connection with this sale transaction. New Facilities Lease On July 13, 2015, the Company entered into a sublease (the "Sublease") that became effective July 22, 2015, to sublet certain premises consisting of 10,141 square feet of space (the "Subleased Premises") located at 101 Hudson Street, Jersey City, New Jersey from Optimer Pharmaceutical, Inc. The term of the Sublease commences on August 1, 2015 (the "Commencement Date") and is scheduled to expire on July 30, 2018. No base rent is due under the Sublease until one month after the Commencement Date. Under the Sublease, the Company is obligated to pay monthly base rent of approximately $25 per month, which amount increases by 3% annually on each anniversary of the Commencement Date. In addition, the Company was required to fund a security deposit with the sublandlord in the amount of $74 . Compensatory Arrangement with Executive Officer On July 21, 2015, Yves J. Ribeill, Ph.D., President and a member of the Company’s board of directors, resigned as President. Dr. Ribeill will continue to serve on the board of directors. The Company and Dr. Ribeill entered into an agreement, effective July 21, 2015, for certain payments and benefits (the “Separation Agreement”), pursuant to which Dr. Ribeill will receive: (i) a cash payment of approximately $100 upon the effective date of his resignation; (ii) cash severance payments totaling approximately $900 , paid over 12 months commencing with the first payroll period following the resignation date; (iii) a payment representing a contribution Dr. Ribeill can use towards continuing COBRA premiums for medical, dental, and vision group health coverage after the resignation date, and (iv) the vesting and exercisability of all outstanding options held by Dr. Ribeill will be accelerated in full on the effective date of resignation, with the exception of options granted pursuant to the 1999 Plan, and the post-employment option exercise period will be extended from 90 -days to 48 months. As of July 23, 2015, Dr. Ribeill held 84,613 vested options and 183,268 unvested options to purchase shares of the Company’s common stock at a weighted average exercise price of $9.61 and $9.41 per share, respectively.

Summary of Significant Accoun22

Summary of Significant Accounting Policies (Policies)	6 Months Ended
	Jun. 30, 2015
Accounting Policies [Abstract]
Assets Held for Sale	Assets Held for Sale The Company generally considers assets to be held for sale (i) when the transaction has been approved by the board of directors or management vested with authority to approve the transaction, (ii) t he assets are available for immediate sale in their present condition, (iii) the Company has initiated an active program to locate a buyer and other actions required to complete the plan to sell the assets, (iv) consummation of the transaction is probable, (v) the assets are being actively marketed for sale at a price that is reasonable in relation to their current fair value, and (vi) the transaction is expected to qualify for recognition as a completed sale, within one year. Following the classification of property and equipment as held for sale, the Company discontinues depreciating the asset and writes down the asset to the lower of carrying value or fair market value, if needed. As described in Note 14, on May 4, 2015, actions taken by the Company's board of directors caused the Company to meet the relevant criteria for reporting the Services Business as held for sale.
Concentration of Credit Risk	Concentration of Credit Risk Financial instruments, which potentially expose the Company to concentrations of credit risk consist principally of cash on deposit with a bank, which exceeds the FDIC insurance limits, as well as accounts receivable and unbilled services. Ongoing credit evaluations of the bank and customers' financial condition and independent ratings are reviewed by the Company. Collateralization of deposits has not been required.
Deferred Offering Costs	Deferred Offering Costs Deferred offering costs are expenses directly related to the IPO or the April 2015 Offering. These costs consist of legal, accounting, printing, and filing fees that the Company has capitalized, including fees incurred by the independent registered public accounting firm directly related to the offerings. The IPO deferred offering costs were offset against the IPO proceeds in May 2014 and were reclassified to additional paid-in capital upon completion of the IPO. Deferred costs associated with the April 2015 Offering were offset against the proceeds from the April 2015 Offering and were reclassified to additional paid-in capital upon completion of the April 2015 Offering.
Revenue Recognition and Deferred Revenue	Revenue Recognition and Deferred Revenue The Company historically derived the majority of its revenue from providing contract research and development services under fee for service arrangements, which were provided by the Company's Services Business that was sold in July 2015 (see Notes 1 and 15). The Company also has entered into collaboration arrangements in exchange for non-refundable upfront payments and consideration as services are performed. These arrangements include multiple elements, such as the sale of licenses and the provision of services. Under these arrangements, the Company also is entitled to receive development milestone payments and royalties in the form of a designated percentage of product sales. The Company classifies non-refundable upfront payments, milestone payments and royalties received under collaboration and licensing agreements as revenues within its statements of operations because the Company views such activities as being central to its business operations. Revenue is recognized when all of the following conditions are met: (i) persuasive evidence of an arrangement exists, (ii) delivery has occurred or services have been rendered, (iii) fees are fixed or determinable, and (iv) collection of fees is reasonably assured. The Company’s contract research and development services revenue was recognized in the period in which the services were performed. When entering into an arrangement, the Company first determines whether the arrangement includes multiple deliverables and is subject to accounting guidance in ASC subtopic 605-25, Multiple-Element Arrangements . If the Company determines that an arrangement includes multiple elements, it determines whether the arrangement should be divided into separate units of accounting and how the arrangement consideration should be measured and allocated among the separate units of accounting. An element qualifies as a separate unit of accounting when the delivered element has standalone value to the customer. The Company’s arrangements do not include a general right of return relative to delivered elements. Any delivered elements that do not qualify as separate units of accounting are combined with other undelivered elements within the arrangement as a single unit of accounting. If the arrangement constitutes a single combined unit of accounting, the Company determines the revenue recognition method for the combined unit of accounting and recognizes the revenue over the period from inception through the date the last deliverable within the single unit of accounting is delivered. Non-refundable upfront license fees are recorded as deferred revenue and recognized into revenue on a straight-line basis over the estimated period of the Company’s substantive performance obligations. If the Company does not have substantive performance obligations, the Company recognizes non-refundable upfront fees into revenue through the date the deliverable is satisfied. Analyzing the arrangement to identify deliverables requires the use of judgment and each deliverable may be an obligation to deliver services, a right or license to use an asset, or another performance obligation. In arrangements that include license rights and other non-contingent deliverables, such as participation in a steering committee, these deliverables do not have standalone value because the non-contingent deliverables are dependent on the license rights. That is, the non-contingent deliverables would not have value without the license rights, and only the Company can perform the related services. Upfront license rights and non-contingent deliverables, such as participation in a steering committee, do not have standalone value as they are not sold separately and they cannot be resold. In addition, when non-contingent deliverables are sold with upfront license rights, the license rights do not represent the culmination of a separate earnings process. As such, the Company accounts for the license and the non-contingent deliverables as a single combined unit of accounting. In such instances, the license revenue in the form of non-refundable upfront payments is deferred and recognized over the applicable relationship period, which historically has been the estimated period of the Company’s substantive performance obligations or the period the rights granted are in effect. The Company recognizes contingent event-based payments under license agreements when the payments are received. The Company has not received any royalty payments to date. The Company will recognize a milestone payment when earned if it is substantive and the Company has no ongoing performance obligations related to the milestone. A milestone payment is considered substantive if it: 1) is commensurate with either the Company’s performance to achieve the milestone or the enhanced value of the delivered item as a result of a specific outcome from the Company’s performance to achieve the milestone; 2) relates solely to past performance; and 3) is reasonable relative to all of the deliverables and payment terms, including other potential milestone consideration, within the arrangement. Amounts received prior to satisfying all revenue recognition criteria are recorded as deferred revenue in the accompanying balance sheets. The Company’s deferred revenue includes non-refundable upfront payments received under certain licensing and collaboration arrangements that contain substantive performance obligations that the Company is providing over respective defined service or estimated relationship periods. Such non-refundable upfront payments are recognized over these defined service or estimated relationship periods.
Collaboration Arrangements	Collaboration Arrangements The Company assesses its contractual arrangements, and presents costs incurred and payments received under contractual arrangements, in accordance with FASB ASC 808, Collaborative Arrangements (Topic 808), when the Company determines that the contractual arrangement includes a joint operating activity, has active participation by both parties, and both parties are subject to significant risks and rewards under the arrangement. When reimbursement payments are due to the Company under a collaborative arrangement within the scope of Topic 808, the Company determines the appropriate classification for each specific reimbursement payment in the statements of operations by considering (i) the nature of the arrangement, (ii) the nature of the Company’s business operations, and (iii) the contractual terms of the arrangement. The Company's August 2013 development, license, and supply agreement with R-Pharm, CJSC (“R-Pharm”), combined with the supplemental arrangement in November 2014, is a collaborative arrangement pursuant to Topic 808 and the Company’s previously described accounting policy. The reimbursements due from R-Pharm for specified research and development costs incurred by the Company are classified as a reduction to research and development expense in the accompanying statements of operations. The reimbursements due to the Company are recorded as a reduction of expense when (i) the reimbursable expenses have been incurred by the Company, (ii) persuasive evidence of a cost reimbursement arrangement exists, (iii) reimbursable costs are fixed or determinable, and (iv) the collection of the reimbursement payment is reasonably assured. The Company recorded receivables for unpaid reimbursement amounts due from R-Pharm of $777 and $226 as of June 30, 2015 and December 31, 2014, respectively, which are presented as other current assets in the accompanying balance sheets.
Research and Development	Research and Development Major components of research and development costs include clinical trial activities and services, including related drug formulation, manufacturing, and other development, preclinical studies, cash compensation, stock-based compensation, fees paid to consultants and other entities that conduct certain research and development activities on the Company’s behalf, materials and supplies, legal services, and regulatory compliance. The Company is required to estimate its expenses resulting from its obligations under contracts with clinical research organizations, clinical site agreements, vendors, and consultants in connection with conducting SCY-078 clinical trials and preclinical development. The financial terms of these contracts are subject to negotiations which vary from contract to contract, and may result in payment flows that do not match the periods over which materials or services are provided to the Company under such contracts. The Company’s objective is to reflect the appropriate development and trial expenses in its financial statements by matching those expenses with the period in which the services and efforts are expended. For clinical trials, the Company accounts for these expenses according to the progress of the trial as measured by actual hours expended by CRO personnel, investigator performance or completion of specific tasks, patient progression, or timing of various aspects of the trial. For preclinical development services performed by outside service providers, the Company determines accrual estimates through financial models, taking into account development progress data received from outside service providers and discussions with applicable Company and service provider personnel. Reimbursements of certain research and development costs by parties under collaborative arrangements have been recorded as a reduction of research and development expense presented within the statement of operations.
Effect of Recent Accounting Pronouncements	Effect of Recent Accounting Pronouncements In April 2014, the FASB issued ASU 2014-08, Reporting Discontinued Operations and Disclosures of Disposals of Components of an Entity , or ASU 2014-08. Under ASU 2014-08, only disposals representing a strategic shift in operations that have a major effect on the Company’s operations and financial results should be presented as discontinued operations. Additionally, ASU 2014-08 requires expanded disclosures about discontinued operations that will provide financial statement users with more information about the assets, liabilities, income, and expenses of discontinued operations. The amendments in ASU 2014-08 are effective for fiscal years, and interim periods within those years, beginning after December 15, 2014. The Company adopted this guidance in the first quarter of 2015 and has applied it in the accompanying interim financial statements for presentation and disclosure of the Services Business as discontinued operations (see Note 14). The Company will also apply, as applicable, the guidance to future dispositions or classifications as held for sale. In May 2014, the FASB issued ASU No. 2014-09, Revenue from Contracts with Customers: Topic 606, or ASU 2014-09. ASU 2014-09 establishes the principles for recognizing revenue and develops a common revenue standard for U.S. GAAP. The standard outlines a single comprehensive model for entities to use in accounting for revenue arising from contracts with customers and supersedes most current revenue recognition guidance, including industry-specific guidance. In applying the new revenue recognition model to contracts with customers, an entity: (1) identifies the contract(s) with a customer; (2) identifies the performance obligations in the contract(s); (3) determines the transaction price; (4) allocates the transaction price to the performance obligations in the contract(s); and (5) recognizes revenue when (or as) the entity satisfies a performance obligation. The accounting standards update applies to all contracts with customers except those that are within the scope of other topics in the FASB Accounting Standards Codification. The accounting standards update also requires significantly expanded quantitative and qualitative disclosures regarding the nature, amount, timing and uncertainty of revenue and cash flows arising from contracts with customers. This guidance is effective for fiscal years and interim periods within those years beginning after December 15, 2016, which is effective for the Company for the year ending December 31, 2017. The FASB delayed in the effective date of the accounting standards update to fiscal years and interim periods within those years beginning on or after December 15, 2017, which is pending approval. The Company is currently evaluating the impact that the implementation of ASU 2014-09 will have on the Company’s financial statements. In August 2014, the FASB issued ASU No. 2014-15, Disclosure of Uncertainties about an Entity’s Ability to Continue as a Going Concern , or ASU 2014-15. ASU 2014-15 will explicitly require management to assess an entity’s ability to continue as a going concern, and to provide related footnote disclosure in certain circumstances. The new standard will be effective for all entities in the first annual period ending after December 15, 2016. Earlier adoption is permitted. The Company is not early adopting ASU 2014-15. The Company is currently evaluating the impact that the implementation of ASU 2014-15 will have on the Company’s financial statements, and the actual impact will be dependent upon the Company’s liquidity and the nature or significance of future events or conditions that exist upon adopting the updated standard. In January 2015, the FASB issued ASU No. 2015-01, Simplifying Income Statement Presentation by Eliminating the Concept of Extraordinary Items, or ASU 2015-01. ASU 2015-01 eliminates from GAAP the concept of extraordinary items. ASU 2015-01 is effective for fiscal years and interim periods beginning after December 15, 2015. Early adoption is permitted. The Company does not expect that the adoption of ASU 2015-01 will have a material impact on its consolidated financial statements. In April 2015, the FASB issued ASU No. 2015-03, Simplifying the Presentation of Debt Issuance Costs , or ASU 2015-03. Under ASU 2015-03, the costs of issuing debt will no longer be recorded as an intangible asset, except when incurred before receipt of the funding from the associated debt liability. Rather, debt issuance costs related to a recognized debt liability will be presented on the balance sheet as a direct deduction from the debt liability, similar to the presentation of debt discounts. The costs will continue to be amortized to interest expense using the effective interest method. ASU 2015-03 is effective for fiscal years and interim periods beginning after December 15, 2015, with early adoption permitted. ASU 2015-03 requires retrospective application to all prior periods presented in the financial statements. The Company does not expect that the adoption of ASU 2015-03 will have a material any impact on its consolidated financial statements. In April 2015, the FASB issued ASU No. 2015-05, Customer’s Accounting for Fees Paid in a Cloud Computing Arrangement” , or ASU 2015-05 . ASU 2015-05 provides guidance to entities about whether a cloud computing arrangement includes a software license. Under ASU 2015-05, if a software cloud computing arrangement contains a software license, entities should account for the license element of the arrangement in a manner consistent with the acquisition of other software licenses. If the arrangement does not contain a software license, entities should account for the arrangement as a service contract. ASU 2015-05 also removes the requirement to analogize to ASC 840-10, to determine the asset acquired in a software licensing arrangement. For public companies, ASU 2015-05 is effective for annual periods, including interim periods within those annual periods, beginning after December 15, 2015, and early adoption is permitted. The Company does not expect that the adoption of ASU 2015-05 will have a material impact on its consolidated financial statements.

Summary of Significant Accoun23

Summary of Significant Accounting Policies (Tables)	6 Months Ended
	Jun. 30, 2015
Accounting Policies [Abstract]
Research and development expenses and reimbursements due	Such reimbursements were recognized under the collaboration arrangement with R-Pharm during the three and six months ended June 30, 2015 . Information about the Company’s research and development expenses and reimbursements due under collaboration arrangements for the three and six months ended June 30, 2015 and 2014, is presented as follows: Three months ended June 30, Six months ended June 30, 2015 2014 2015 2014 Research and development expense, gross $ 3,820 $ 1,823 7,801 3,143 Less: Reimbursement of research and development expense 538 — 732 — Research and development expense, net of reimbursements $ 3,282 $ 1,823 7,069 3,143

Property and Equipment (Tables)

Property and Equipment (Tables)	6 Months Ended
	Jun. 30, 2015
Property, Plant and Equipment [Abstract]
Summary of Property and Equipment	Property and equipment consists of the following: June 30, December 31, Equipment $ 9,046 $ 8,552 Furniture and fixtures 375 375 Leasehold improvements 13,212 13,193 Total property and equipment 22,633 22,120 Less accumulated depreciation 17,732 17,285 Property and equipment, net of accumulated depreciation 4,901 4,835 Less impairment charge on classification of property and equipment as assets held for sale 1,350 — Property and equipment, net of accumulated depreciation and impairment charge 3,551 4,835 Property and equipment reclassified to assets held for sale, net (3,551 ) (4,835 ) Property and equipment, net of assets classified as held for sale $ — $ —

Commitments and Contingencies (

Commitments and Contingencies (Tables)	6 Months Ended
	Jun. 30, 2015
Commitments and Contingencies Disclosure [Abstract]
Future Minimum Lease Payments	Future minimum lease payments for all operating leases as of June 30, 2015 are as follows: 2015 $ 550 2016 1,122 2017 1,140 2018 1,161 2019 291 Thereafter — Total $ 4,264

Common Stock (Tables)

Common Stock (Tables)	6 Months Ended
	Jun. 30, 2015
Equity [Abstract]
Summary of Common Stock Shares Activity	The following table summarizes common stock share activity for the six months ended June 30, 2015 : Shares of Common Stock Balance, December 31, 2014 8,512,103 Common stock issued through April 2015 Offering 5,376,622 Common stock issued through employee stock purchase plan 15,107 Balance, June 30, 2015 13,903,832
Schedule of Reserved Shares of Common Stock for Future Issuance	The Company had reserved shares of common stock for future issuance as follows: As of As of June 30, December 31, Outstanding stock options 1,153,369 615,322 Outstanding Series C-1 Preferred warrants 14,033 14,033 For possible future issuance under 2014 Equity Incentive Plan (Note 8) 618,773 180,610 For possible future issuance under Employee Stock Purchase Plan (Note 8) 52,050 37,746 For possible future issuance under 2015 Inducement Plan (Note 8) 325,000 — Total common shares reserved for future issuance 2,163,225 847,711

Stock-based Compensation (Table

Stock-based Compensation (Tables)	6 Months Ended
	Jun. 30, 2015
Disclosure of Compensation Related Costs, Share-based Payments [Abstract]
Stock-Based Compensation Expense Related to Stock Options	Stock-based compensation expense related to stock options is included in the following line items in the accompanying statements of operations: Three Months Ended June 30, Six Months Ended June 30, 2015 2014 2015 2014 Research and development 62 100 114 162 Selling, general and administrative 689 135 900 170 Discontinued operations 68 37 101 50 $ 819 $ 272 $ 1,115 $ 382

Net Loss Per Share (Tables)

Net Loss Per Share (Tables)	6 Months Ended
	Jun. 30, 2015
Earnings Per Share [Abstract]
Summary of Computation of Basic and Diluted Net Income (Loss) Per Share	The following table summarizes the computation of basic and diluted net loss per share attributable to the Company’s common stockholders: Three Months Ended Six Months Ended 2015 2014 2015 2014 Income (loss) attributable to common stock - basic: Income (loss) from continuing operations $ (6,492 ) $ 1,671 $ (12,423 ) $ 1,403 Deemed dividend for beneficial conversion feature on Series D-2 Preferred — — — (909 ) Deemed dividend for antidilution adjustments to convertible preferred stock — — — (214 ) Accretion of convertible preferred stock — — — (510 ) Allocation of net income to convertible preferred stockholders — (262 ) — (303 ) Income (loss) from continuing operations attributable to common stock - basic (6,492 ) 1,409 (12,423 ) (533 ) Income (loss) from discontinued operations attributable to common stock - basic (3,005 ) 562 (3,458 ) 1,242 Net income (loss) attributable to common stock - basic $ (9,497 ) $ 1,971 $ (15,881 ) $ 709 Income (loss) attributable to common stock - diluted: Income (loss) from continuing operations attributable to common stock - basic $ (6,492 ) $ 1,409 $ (12,423 ) $ (533 ) Derivative fair value adjustment — (7,297 ) — (10,080 ) Loss from continuing operations attributable to common stock - diluted (6,492 ) (5,888 ) (12,423 ) (10,613 ) Loss from discontinued operations attributable to common stock - diluted (3,005 ) 562 (3,458 ) 1,242 Net income (loss) attributable to common stock - diluted $ (9,497 ) $ (5,326 ) $ (15,881 ) $ (9,371 ) Weighted-average common shares outstanding: Weighted-average common shares outstanding - basic 12,249,487 5,181,174 10,393,289 2,771,020 Allocation of common stock warrants as participating securities — 273,197 — 273,709 Weighted-average common shares outstanding - diluted 12,249,487 5,454,371 10,393,289 3,044,729 Income (loss) per share - basic: Continuing operations $ (0.53 ) $ 0.27 $ (1.20 ) $ (0.19 ) Discontinued operations (0.25 ) 0.11 (0.33 ) 0.45 Net income (loss) per share - basic $ (0.78 ) $ 0.38 $ (1.53 ) $ 0.26 Income (loss) per share - diluted: Continuing operations $ (0.53 ) $ (1.08 ) $ (1.20 ) $ (3.49 ) Discontinued operations (0.25 ) 0.10 (0.33 ) 0.41 Net income (loss) per share - diluted $ (0.78 ) $ (0.98 ) $ (1.53 ) $ (3.08 )
Summary of Antidilutive Securities Excluded from Computation of Weighted Average Common Stock Outstanding	The following securities, presented on a common stock equivalent basis, have been excluded from the calculation of weighted average common shares outstanding because their effect is anti-dilutive. Three Months Ended Six Months Ended 2015 2014 2015 2014 Convertible preferred stock: Series A Preferred — 6,149 — 6,149 Series B Preferred — 131,685 — 131,685 Series C Preferred — 783,515 — 783,515 Series C-2 Preferred — 173,213 — 173,213 Series D-1 Preferred — 296,773 — 296,773 Series D-2 Preferred — 300,549 — 300,549 Series C-1 Preferred warrants 14,033 14,033 14,033 14,033 Stock options 1,153,369 215,467 1,153,369 215,467 ESPP 7,298 — 7,298 —

Related-Party Transactions (Tab

Related-Party Transactions (Tables)	6 Months Ended
	Jun. 30, 2015
Related Party Transactions [Abstract]
Summary of Transactions with Related Parties	The Company had transactions with related parties as follows: Three Months Ended June 30, Six Months Ended June 30, 2015 2014 2015 2014 Revenue $ 988 $ 1,822 $ 1,975 $ 3,644 Selling, general and administrative expense $ — $ 500 $ — $ 500

Fair Value Measurements (Tables

Fair Value Measurements (Tables)	6 Months Ended
	Jun. 30, 2015
Fair Value Disclosures [Abstract]
Summary of Reconciliation of Beginning and Ending Balances for Liabilities Measured at Fair Value on Recurring Basis	A reconciliation of the beginning and ending balances for liabilities measured at fair value on a recurring basis using significant unobservable inputs (Level 3) is as follows: Three months ended Six months ended June 30, 2014 June 30, 2014 Balance at beginning of period $ 9,998 $ 12,237 Issuance of warrants — 544 Excess of fair value of warrants over proceeds — 362 Adjustment to fair value (7,297 ) (10,442 ) Reclassification to additional paid-in capital upon exercise of warrants (2,701 ) (2,701 ) Balance at end of period $ — $ —

Discontinued Operations, Asse31

Discontinued Operations, Assets Held for Sale, Impairment Charges (Tables)	6 Months Ended
	Jun. 30, 2015
Discontinued Operations and Disposal Groups [Abstract]
Discontinued Operations Financial Statement Impact	The following table presents revenue, (expenses), gains, and (losses) attributable to discontinued operations: Three months ended June 30, Six months ended June 30, 2015 2014 2015 2014 Major line items constituting income (loss) of discontinued operations: Total revenue $ 3,617 $ 4,577 $ 6,849 $ 9,217 Cost of revenue (3,599 ) (4,180 ) (6,830 ) (8,140 ) Research and development (422 ) — (853 ) — Selling, general and administrative (198 ) — (221 ) — Gain on insurance recovery — 165 — 165 Severance and exit costs (Note 13) (1,053 ) — (1,053 ) — Impairment charge from classification of assets as held for sale (1,350 ) — (1,350 ) — Income (loss) from discontinued operations $ (3,005 ) $ 562 $ (3,458 ) $ 1,242 The following table presents depreciation, capital expenditures, and significant operating and investing non-cash items related to the discontinued operations: Six months ended June 30, 2015 2014 Depreciation expense $ 391 $ 562 Purchases of property and equipment (527 ) (323 ) Stock-based compensation 101 50 Changes in deferred rent (122 ) (56 ) Equipment purchases in accounts payable and accrued expenses 20 6 The following table presents a reconciliation of the carrying amounts of assets and liabilities of the Services Business to assets held for sale, net in the balance sheets: June 30, 2015 December 31, 2014 Carrying amounts of assets included as part of discontinued operations: Accounts and unbilled receivables, net $ 1,715 $ 1,501 Prepaid expenses and other current assets 761 289 Property and equipment, net 4,901 4,835 Other assets 59 76 Disposal loss recognized on classification as held for sale (1,350 ) — Assets held for sale, net $ 6,086 $ 6,701 Carrying amounts of liabilities included as part of discontinued operations: Accounts payable and accrued expenses $ 546 $ 681 Deferred revenue 381 445 Deferred rent 1,172 1,294 Liabilities related to assets held for sale $ 2,099 $ 2,420

Description of Business and B32

Description of Business and Basis of Preparation - Additional Information (Detail) $ / shares in Units, $ in Thousands	Apr. 28, 2015USD ($)$ / sharesshares	May. 31, 2014shares	May. 07, 2014USD ($)$ / sharesshares	Apr. 25, 2014	Mar. 17, 2014	Jun. 30, 2015shares
Organization Consolidation And Presentation Of Financial Statements Disclosure [Line Items]
Formation date						Nov. 4, 1999
Reverse stock split ratio, description					1-for-4 reverse stock split
Reverse stock split ratio					0.25
Number of shares of common stock sold | shares	5,376,622		6,200,000			5,376,622
Public offering price per share | $ / shares	$ 7.7000		$ 10
Net proceeds from initial public offering (IPO)			$ 54,583
Underwriting discounts and commissions			3,290
Offering expenses			$ 4,127
Number of outstanding shares of convertible preferred stock converted into common stock | shares			1,691,884
Outstanding warrants exercised | shares		275,687	275,687
Proceeds from public offerings	$ 38,012
Underwriting fees and offering costs	$ 3,388
Additional Reverse Stock Split [Member]
Organization Consolidation And Presentation Of Financial Statements Disclosure [Line Items]
Reverse stock split ratio, description				1-for-5.1 reverse stock split
Reverse stock split ratio				0.196
2013 Credit Agreement [Member]
Organization Consolidation And Presentation Of Financial Statements Disclosure [Line Items]
Repayment of debt			$ 15,000

Summary of Significant Accoun33

Summary of Significant Accounting Policies - Additional Information (Detail) - USD ($) $ in Thousands	1 Months Ended		3 Months Ended		6 Months Ended
	Jan. 31, 2014	Aug. 31, 2013	Jun. 30, 2015	Jun. 30, 2014	Jun. 30, 2015	Jun. 30, 2014	Dec. 31, 2014
Income Statement, Balance Sheet and Additional Disclosures by Disposal Groups, Including Discontinued Operations [Line Items]
Royalty payments received					$ 0
Upfront payment received		$ 1,500
Deferred revenue recognition period		70 months
Revenue recognized from upfront payments			$ 64	$ 65	129	$ 130
Receivables due from R-Pharm			777		777		$ 226
Services Business [Member]
Income Statement, Balance Sheet and Additional Disclosures by Disposal Groups, Including Discontinued Operations [Line Items]
Upfront payment received	$ 500
Deferred revenue recognition period	48 months
Discontinued Operations, Held-for-sale [Member] | Services Business [Member]
Income Statement, Balance Sheet and Additional Disclosures by Disposal Groups, Including Discontinued Operations [Line Items]
Discontinued operation revenue			3,617	4,577	6,849	9,217
Discontinued Operations, Held-for-sale [Member] | Licensing Agreements [Member] | Services Business [Member]
Income Statement, Balance Sheet and Additional Disclosures by Disposal Groups, Including Discontinued Operations [Line Items]
Discontinued operation revenue			$ 31	$ 31	$ 63	$ 59

Summary of Significant Accoun34

Summary of Significant Accounting Policies - Schedule of Research and Development Expenses (Details) - USD ($) $ in Thousands	3 Months Ended		6 Months Ended
	Jun. 30, 2015	Jun. 30, 2014	Jun. 30, 2015	Jun. 30, 2014
Accounting Policies [Abstract]
Research and development expense, gross	$ 3,820	$ 1,823	$ 7,801	$ 3,143
Less: Reimbursement of research and development expense	538	0	732	0
Research and development expense, net of reimbursements	$ 3,282	$ 1,823	$ 7,069	$ 3,143

Property and Equipment - Summar

Property and Equipment - Summary of Property and Equipment (Detail) - USD ($) $ in Thousands	Jun. 30, 2015	Dec. 31, 2014
Property, Plant and Equipment [Line Items]
Property and equipment	$ 22,633	$ 22,120
Less accumulated depreciation	17,732	17,285
Property and equipment, net of accumulated depreciation	4,901	4,835
Less impairment charge on classification of property and equipment as assets held for sale	1,350	0
Property and equipment, net of accumulated depreciation and impairment charge	3,551	4,835
Property and equipment, net of accumulated depreciation	(3,551)	(4,835)
Property and equipment, net of accumulated depreciation	0	0
Equipment [Member]
Property, Plant and Equipment [Line Items]
Property and equipment	9,046	8,552
Furniture and fixtures [Member]
Property, Plant and Equipment [Line Items]
Property and equipment	375	375
Leasehold improvements [Member]
Property, Plant and Equipment [Line Items]
Property and equipment	$ 13,212	$ 13,193

Property and Equipment - Additi

Property and Equipment - Additional Information (Detail) - USD ($) $ in Thousands	3 Months Ended		6 Months Ended
	Jun. 30, 2015	Jun. 30, 2014	Jun. 30, 2015	Jun. 30, 2014
Property, Plant and Equipment [Abstract]
Depreciation expense	$ 124	$ 307	$ 447	$ 615

Debt Obligations - Additional I

Debt Obligations - Additional Information (Detail) - USD ($)	May. 07, 2014	Mar. 08, 2013	Jun. 30, 2015	Jun. 30, 2014	Jun. 30, 2015	Jun. 30, 2014	Apr. 28, 2015	Dec. 31, 2014	Jun. 30, 2013	Dec. 31, 2011	Apr. 30, 2010
Debt Instrument [Line Items]
Loss on extinguishment of debt			$ 0	$ (1,389,000)	$ 0	$ (1,389,000)
Amortization of deferred financing costs			$ 0	219,000	$ 0	755,000
Number of warrants issued to purchase common stock			14,033		14,033			14,033
Exercise price of warrants	$ 10						$ 7.7000
2010 Credit Agreement [Member]
Debt Instrument [Line Items]
Credit facility agreement amount											$ 15,000,000
2013 Credit Agreement [Member]
Debt Instrument [Line Items]
Deemed contribution of a loan guarantee		$ 3,930,000
Outstanding debt plus accrued interest	$ 15,000,000
Loss on extinguishment of debt				1,389,000
Debt outstanding			$ 0		$ 0			$ 0
Amortization of deferred financing costs			0	$ 219,000	0	$ 755,000
December 2011 Note and Warrant Agreement [Member]
Debt Instrument [Line Items]
Debt agreement, maximum borrowing capacity										$ 15,000,000
2011-2012 Notes [Member]
Debt Instrument [Line Items]
Exercise price of warrants										$ 0.20
Convertible notes aggregate amount			0		0			0
Interest payable			0		0			0
June 2013 Note and Warrant Agreement [Member]
Debt Instrument [Line Items]
Debt agreement, maximum borrowing capacity									$ 1,500,000
Convertible notes aggregate amount			0		0			0	$ 899,000
Interest payable			$ 0		$ 0			$ 0
Investor [Member] | 2011-2012 Notes [Member]
Debt Instrument [Line Items]
Number of warrants issued to purchase common stock										26,000
Convertible notes aggregate amount										$ 11,444,000
Term Loan [Member] | 2010 Credit Agreement [Member]
Debt Instrument [Line Items]
Credit facility agreement amount											5,000,000
Revolving Credit Facility [Member] | 2010 Credit Agreement [Member]
Debt Instrument [Line Items]
Credit facility agreement amount											$ 10,000,000
London Interbank Offered Rate (LIBOR) [Member] | 2010 Credit Agreement [Member]
Debt Instrument [Line Items]
Interest at a rate of London InterBank plus											0.95%

Commitments and Contingencies -

Commitments and Contingencies - Additional Information (Detail)	Jul. 21, 2015USD ($)	Jun. 30, 2015USD ($)Agreement	Jun. 30, 2014	Jun. 30, 2015USD ($)Agreement	Jun. 30, 2014USD ($)	Jun. 30, 2015USD ($)Agreement	Jun. 30, 2014USD ($)
Commitment And Contingencies [Line Items]
Rent expense				$ 219,000	$ 236,000	$ 437,000	$ 467,000
Number of additional license agreements | Agreement		2		2		2
License agreements fee		$ 2,300,000		$ 2,300,000		$ 2,300,000
Services agreement, days required between notice and termination of agreement			30 days
Maximum [Member]
Commitment And Contingencies [Line Items]
Milestone payments from the Company						19,000,000
Discontinued Operations, Disposed of by Sale [Member]
Commitment And Contingencies [Line Items]
Success fee payable		$ 500,000		$ 500,000		$ 500,000
Percentage of transaction consideration		4.00%		4.00%		4.00%
Discontinued Operations, Disposed of by Sale [Member] | Subsequent Event [Member]
Commitment And Contingencies [Line Items]
Payment of success fee	$ 450,000
Discontinued Operations, Held-for-sale [Member]
Commitment And Contingencies [Line Items]
Payment of success fee		$ 50,000

Commitments and Contingencies39

Commitments and Contingencies - Future Minimum Lease Payments (Detail) $ in Thousands	Jun. 30, 2015USD ($)
Commitments and Contingencies Disclosure [Abstract]
2,015	$ 550
2,016	1,122
2,017	1,140
2,018	1,161
2,019	291
Thereafter	0
Total	$ 4,264

Convertible Preferred Stock - A

Convertible Preferred Stock - Additional Information (Detail) - USD ($)	Apr. 28, 2015	Mar. 13, 2014	Jan. 31, 2014	Dec. 11, 2013	Jul. 31, 2006	Jun. 30, 2015	Jun. 30, 2014	Jun. 30, 2015	Jun. 30, 2014	Dec. 31, 2014	May. 31, 2014	May. 07, 2014
Temporary Equity [Line Items]
IPO proceeds that triggers conversion of preferred stock		$ 20,000,000
Number of outstanding shares of convertible preferred stock converted into common stock												1,691,884
Outstanding Series C-1 Preferred warrants						14,033		14,033		14,033
Exercise price of warrants											$ 0.20
Other (expense) income related to fair value adjustment of long term derivative liability							$ 7,297,000		$ 10,442,000
Proceeds from sale of preferred stock								$ 0	544,000
Stock issuance costs	$ 3,388,000
Excess of fair value of warrants over proceeds							0		362,000
Series C-1 Convertible Preferred Stock [Member]
Temporary Equity [Line Items]
Outstanding Series C-1 Preferred warrants					196,923
Exercise price of warrants					$ 3.25
Warrant expiration date								May 7, 2019
Fair value of warrants					$ 459,000
Other (expense) income related to fair value adjustment of long term derivative liability						$ 0	$ 0	$ 0	$ 37,000
Common Stock [Member]
Temporary Equity [Line Items]
Outstanding Series C-1 Preferred warrants					14,033
Exercise price of warrants					$ 45.61
Series D-2 Preferred [Member]
Temporary Equity [Line Items]
Outstanding Series C-1 Preferred warrants			19,048	87,532
Exercise price of warrants			$ 0.20	$ 0.20
Fair value of warrants			$ 906,000	$ 4,214,000
Convertible preferred stock, shares			388,641	1,785,712
Convertible preferred stock, price per share			$ 1.40	$ 1.40
Proceeds from sale of preferred stock			$ 544,000	$ 2,500,000
Stock issuance costs				95,000
Excess of fair value of warrants over proceeds			$ 362,000	$ 1,714,000

Common Stock - Additional Infor

Common Stock - Additional Information (Detail) - USD ($) $ / shares in Units, $ in Thousands	May. 31, 2014	May. 07, 2014	May. 02, 2014	Dec. 11, 2013	Jun. 30, 2015	Jun. 30, 2014	Jun. 30, 2015	Jun. 30, 2014	Dec. 31, 2014	Mar. 31, 2014	Dec. 31, 2013	Dec. 31, 2011
Schedule of Capitalization, Equity [Line Items]
Common stock, par value					$ 0.001		$ 0.001		$ 0.001
Common stock, shares authorized					125,000,000		125,000,000		125,000,000
Common stock, shares issued					13,903,832		13,903,832		8,512,103
Number of warrants issued to purchase common stock					14,033		14,033		14,033
Exercise price of warrants	$ 0.20
Exercise of common stock warrants	275,687	275,687
Fair value of common stock warrant derivative liabilities										$ 9,998	$ 12,200
Warrant derivative liability reclassified to additional paid-in capital			$ 2,701
Fair value adjustment of long term derivative liability						$ 7,297		$ 10,442
Common Stock Warrant [Member]
Schedule of Capitalization, Equity [Line Items]
Fair value adjustment of long term derivative liability					$ 0	$ 7,297	$ 0	$ 10,405
2011-2012 Notes [Member]
Schedule of Capitalization, Equity [Line Items]
Number of warrants issued to purchase common stock												26,000
Exercise price of warrants												$ 0.20
June 2013 Note and Warrant Agreement [Member]
Schedule of Capitalization, Equity [Line Items]
Number of warrants issued to purchase common stock				88,987
Exercise price of warrants				$ 0.20
Warrants exercisable date				Jun. 28, 2018
Series D-2 Purchase Agreement [Member]
Schedule of Capitalization, Equity [Line Items]
Number of warrants issued to purchase common stock				87,532
Exercise price of warrants				$ 0.20
Warrants exercisable date				Dec. 11, 2018
Increase in the shares of common stock underlying the warrants issued				54,120
Revised number of common shares underlying the warrants issued				80,120

Common Stock - Summary of Commo

Common Stock - Summary of Common Stock Shares Activity (Detail) - shares	Apr. 28, 2015	May. 07, 2014	Mar. 31, 2015	Jun. 30, 2015
Equity [Abstract]
Beginning Balance			8,512,103	8,512,103
Common stock issued through April 2015 Offering	5,376,622	6,200,000		5,376,622
Common stock issued through employee stock purchase plan			15,107	15,107
Ending Balance				13,903,832

Common Stock - Schedule of Rese

Common Stock - Schedule of Reserved Shares of Common Stock for Future Issuance (Detail) - shares	Jun. 30, 2015	Dec. 31, 2014
Class of Stock [Line Items]
Outstanding stock options	1,153,369	615,322
Outstanding Series C-1 Preferred warrants	14,033	14,033
Total common shares reserved for future issuance	2,163,225	847,711
2014 Equity Incentive Plan [Member]
Class of Stock [Line Items]
Possible future issuance under equity compensation plan (shares)	618,773	180,610
2014 Employee Stock Purchase Plan [Member]
Class of Stock [Line Items]
Possible future issuance under equity compensation plan (shares)	52,050	37,746
2015 Inducement Plan [Member]
Class of Stock [Line Items]
Possible future issuance under equity compensation plan (shares)	325,000	0

Stock-based Compensation - 2009

Stock-based Compensation - 2009 Stock Option Plan (Details) - 6 months ended Jun. 30, 2015 - 2009 Stock Option Plan [Member]	Total
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Expiration period of options	10 years
Minimum [Member]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Percentage of exercise price	100.00%
Vesting period of options	3 years
Maximum [Member]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Percentage of exercise price	110.00%
Vesting period of options	4 years

Stock-based Compensation - 2014

Stock-based Compensation - 2014 Equity Incentive Plan (Details) $ / shares in Units, $ in Thousands	Jun. 04, 2015director$ / sharesshares	Jun. 03, 2015	Apr. 01, 2015shares	Feb. 25, 2015shares	Jan. 01, 2015shares	Jun. 18, 2014shares	May. 02, 2014shares	Jun. 30, 2015USD ($)$ / sharesshares	Jun. 30, 2015USD ($)$ / sharesshares	Dec. 31, 2014shares
2014 Equity Incentive Plan [Member]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Effective date of equity incentive plan							May 2, 2014
Common stock outstanding percentage							4.00%
Number of shares of common stock for future issuance, board of directors prerogative, increase in period							0
Aggregate number of shares of the Company's common stock that may be issued				510,726	340,484	351,653
Options granted in period (shares)			425,967
Expiration period of options			10 years
Possible future issuance under equity compensation plan (shares)								618,773	618,773	180,610
Incremental fair value of outstanding modified options (in usd per share) | $ / shares								$ 3.54
Total additional compensation cost of the post-employment exercise period modification | $								$ 819	$ 819
Additional compensation cost of the post-employment exercise period modification recognized in the period | $								$ 466
2014 Equity Incentive Plan [Member] | Maximum [Member]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Base number of new shares available for future issuance under equity incentive plan							257,352
Common stock issuable period							10 years
2014 Equity Incentive Plan [Member] | Chief Executive Officer [Member]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Options granted in period (shares)			330,000
2014 Equity Incentive Plan [Member] | Director [Member]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Number of directors who resigned | director	3
Options outstanding (in shares)	48,283
Weighted average exercise price, options outstanding | $ / shares	$ 9.01
2014 Equity Incentive Plan [Member] | Director [Member] | Maximum [Member]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Post-employment options, exercise period	48 months
2014 Equity Incentive Plan [Member] | Director [Member] | Minimum [Member]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Post-employment options, exercise period	36 months	90 days
2014 Equity Incentive Plan [Member] | Chief Financial Officer [Member]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Post-employment options, exercise period	36 months
Options outstanding (in shares)								74,490	74,490
Weighted average exercise price, options outstanding | $ / shares								$ 9.53	$ 9.53
Unvested options outstanding (in shares)								50,814	50,814
Weighted average exercise price, unvested options | $ / shares								$ 9.49	$ 9.49
2014 Equity Incentive Plan [Member] | Retention Plan [Member] | Non-executive Employee [Member]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Post-employment options, exercise period	48 months
Options outstanding (in shares)								121,550	121,550
Weighted average exercise price, options outstanding | $ / shares								$ 9.13	$ 9.13
Unvested options outstanding (in shares)								85,990	85,990
Weighted average exercise price, unvested options | $ / shares								$ 8.95	$ 8.95
2014 Equity Incentive Plan [Member] | Services Business [Member] | June 2015 Terminated Employees [Member]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Post-employment options, exercise period	48 months
Options outstanding (in shares)								17,715	17,715
Weighted average exercise price, options outstanding | $ / shares								$ 9.64	$ 9.64
Unvested options outstanding (in shares)								8,331	8,331
Weighted average exercise price, unvested options | $ / shares								$ 9.64	$ 9.64
2009 Stock Option Plan [Member]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Number of additional awards expected to be granted							0
Expiration period of options									10 years

Stock-based Compensation - 2015

Stock-based Compensation - 2015 Inducement Plan (Details) - 2015 Inducement Plan [Member] - shares	3 Months Ended
	Jun. 30, 2015	Mar. 26, 2015	Dec. 31, 2014
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Shares authorized under the plan		450,000
Options granted in period (shares)	125,000
Possible future issuance under equity compensation plan (shares)	325,000		0

Stock-based Compensation - 2047

Stock-based Compensation - 2014 Employee Stock Purchase Plan (Details) - USD ($) $ in Thousands	Feb. 28, 2014	Mar. 31, 2015	Jun. 30, 2015	Dec. 31, 2014
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Common stock issued through employee stock purchase plan		15,107	15,107
2014 Employee Stock Purchase Plan [Member]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Effective date of employee stock purchase plan	May 2, 2014
Common stock issuable period	10 years
Common stock outstanding percentage	0.80%
Employee stock purchase plan, number of shares, which might be added to common stock outstanding	29,411
Number of shares of common stock for future issuance, board of directors prerogative, increase in period	0
Aggregate number of shares of the Company's common stock that may be issued		29,411
Possible future issuance under equity compensation plan (shares)			52,050	37,746
Employee stock purchase plan, employee withholdings to be returned to former employees			$ 59
2014 Employee Stock Purchase Plan [Member] | Maximum [Member]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
For possible future issuance under employee stock purchase plan	47,794

Stock-based Compensation - Comp

Stock-based Compensation - Compensation Cost (Details) - USD ($) $ in Thousands	3 Months Ended		6 Months Ended
	Jun. 30, 2015	Jun. 30, 2014	Jun. 30, 2015	Jun. 30, 2014
Disclosure of Compensation Related Costs, Share-based Payments [Abstract]
Stock-based compensation	$ 819	$ 272	$ 1,115	$ 382
Tax benefit from compensation expense	0	0	0	0
Cash received from option exercised	$ 0	$ 4	$ 0	$ 9

- Stock-based Compensation Expe

- Stock-based Compensation Expense Related to Stock Options (Detail) - USD ($) $ in Thousands	3 Months Ended		6 Months Ended
	Jun. 30, 2015	Jun. 30, 2014	Jun. 30, 2015	Jun. 30, 2014
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Stock-based compensation expense related to stock options	$ 819	$ 272	$ 1,115	$ 382
Research and development [Member]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Stock-based compensation expense related to stock options	62	100	114	162
Selling, general and administrative [Member]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Stock-based compensation expense related to stock options	689	135	900	170
Discontinued operations [Member]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Stock-based compensation expense related to stock options	$ 68	$ 37	$ 101	$ 50

Net Loss Per Share - Summary of

Net Loss Per Share - Summary of Computation of Basic and Diluted Net Income (Loss) Per Share (Detail) - USD ($) $ / shares in Units, $ in Thousands	3 Months Ended		6 Months Ended
	Jun. 30, 2015	Jun. 30, 2014	Jun. 30, 2015	Jun. 30, 2014
Income (loss) attributable to common stock - basic:
Income (loss) from continuing operations	$ (6,492)	$ 1,671	$ (12,423)	$ 1,403
Deemed dividend for beneficial conversion feature on Series D-2 Preferred	0	0	0	(909)
Deemed dividend for antidilution adjustments to convertible preferred stock	0	0	0	(214)
Accretion of convertible preferred stock	0	0	0	(510)
Allocation of net income to convertible preferred stockholders	0	(262)	0	(303)
Income (loss) from continuing operations attributable to common stock - basic	(6,492)	1,409	(12,423)	(533)
Income (loss) from discontinued operations attributable to common stock	(3,005)	562	(3,458)	1,242
Net income (loss) attributable to common stock - basic	(9,497)	1,971	(15,881)	709
Income (loss) attributable to common stock - diluted:
Derivative fair value adjustment	0	(7,297)	0	(10,080)
Loss from continuing operations attributable to common stock - diluted	(6,492)	(5,888)	(12,423)	(10,613)
Net loss attributable to common stockholders - diluted	$ (9,497)	$ (5,326)	$ (15,881)	$ (9,371)
Weighted-average common shares outstanding:
Weighted-average common shares outstanding - basic	12,249,487	5,181,174	10,393,289	2,771,020
Allocation of common stock warrants as participating securities	0	273,197	0	273,709
Weighted-average common shares outstanding - diluted	12,249,487	5,454,371	10,393,289	3,044,729
Income (loss) per share - basic:
Continuing operations, per basic share	$ (0.53)	$ 0.27	$ (1.20)	$ (0.19)
Discontinued operations, per basic share	(0.25)	0.11	(0.33)	0.45
Net income (loss) per share - basic	(0.78)	0.38	(1.53)	0.26
Income (loss) per share - diluted:
Continuing operations, per diluted share	(0.53)	(1.08)	(1.20)	(3.49)
Discontinued operations, per diluted share	(0.25)	0.10	(0.33)	0.41
Net income (loss) per share - diluted	$ (0.78)	$ (0.98)	$ (1.53)	$ (3.08)

Net Loss Per Share - Summary 51

Net Loss Per Share - Summary of Antidilutive Securities Excluded from Computation of Weighted Average Common Stock Outstanding (Detail) - shares	3 Months Ended		6 Months Ended
	Jun. 30, 2015	Jun. 30, 2014	Jun. 30, 2015	Jun. 30, 2014
Series A Preferred [Member]
Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]
Anti-dilutive securities	0	6,149	0	6,149
Series B Preferred [Member]
Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]
Anti-dilutive securities	0	131,685	0	131,685
Series C Preferred [Member]
Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]
Anti-dilutive securities	0	783,515	0	783,515
Series C-2 Preferred [Member]
Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]
Anti-dilutive securities	0	173,213	0	173,213
Series D-1 Preferred [Member]
Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]
Anti-dilutive securities	0	296,773	0	296,773
Series D-2 Preferred [Member]
Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]
Anti-dilutive securities	0	300,549	0	300,549
Series C-1 Preferred warrants [Member] | Series C-1 Preferred [Member]
Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]
Anti-dilutive securities	14,033	14,033	14,033	14,033
Stock options [Member]
Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]
Anti-dilutive securities	1,153,369	215,467	1,153,369	215,467
ESPP [Member]
Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]
Anti-dilutive securities	7,298	0	7,298	0

Related-Party Transactions - Su

Related-Party Transactions - Summary of Transactions with Related Parties (Detail) - USD ($) $ in Thousands	3 Months Ended		6 Months Ended
	Jun. 30, 2015	Jun. 30, 2014	Jun. 30, 2015	Jun. 30, 2014
Related Party Transactions [Abstract]
Revenue	$ 988	$ 1,822	$ 1,975	$ 3,644
Selling, general and administrative expense	$ 0	$ 500	$ 0	$ 500

Related-Party Transactions - Ad

Related-Party Transactions - Additional Information (Details) - USD ($) $ in Thousands	1 Months Ended	3 Months Ended		6 Months Ended
	May. 31, 2015	Jun. 30, 2015	Jun. 30, 2014	Jun. 30, 2015	Jun. 30, 2014
Related Party Transaction [Line Items]
IPO success fee		$ 0	$ 500	$ 0	$ 500
Sanofi [Member]
Related Party Transaction [Line Items]
Ownership percentage of a related party in a customer of the company				100.00%
Sales [Member] | Sanofi [Member]
Related Party Transaction [Line Items]
Percentage of related-party revenue		27.00%	40.00%	29.00%	40.00%
Burrill Securities [Member] | Affiliated Entity [Member]
Related Party Transaction [Line Items]
IPO success fee	$ 500

Fair Value Measurements - Addit

Fair Value Measurements - Additional Information (Details) - USD ($) $ in Thousands	May. 04, 2015	Jun. 30, 2015	Jun. 30, 2014	Jun. 30, 2015	Jun. 30, 2014
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Impairment charge from classification of assets as held for sale		$ (1,350)		$ (1,350)	$ 0
Nonrecurring Adjustment [Member]
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Fair value adjustment	$ 572
Estimated selling costs	778
Discontinued Operations, Held-for-sale [Member] | Services Business [Member]
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Impairment charge from classification of assets as held for sale		(1,350)	$ 0	$ (1,350)	$ 0
Discontinued Operations, Held-for-sale [Member] | Services Business [Member] | Nonrecurring Adjustment [Member]
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Impairment charge from classification of assets as held for sale	$ (1,350)	$ (1,350)

Fair Value Measurements - Recon

Fair Value Measurements - Reconciliation of Fair Value of Liabilities (Details) - USD ($) $ in Thousands	3 Months Ended	6 Months Ended
	Jun. 30, 2014	Jun. 30, 2015	Jun. 30, 2014
Fair Value, Liabilities Measured on Recurring Basis, Unobservable Input Reconciliation, Calculation [Roll Forward]
Beginning balance	$ 9,998		$ 12,237
Issuance of warrants	0		544
Excess of fair value of warrants over proceeds	0		362
Adjustment to fair value	(7,297)		(10,442)
Reclassification to additional paid-in capital upon exercise of warrants	(2,701)	$ 0	(2,701)
Ending balance	$ 0		$ 0

Compensatory Plan Obligations (

Compensatory Plan Obligations (Details) - USD ($)	Jul. 21, 2015	Jun. 30, 2015	Dec. 31, 2014
Restructuring Cost and Reserve [Line Items]
Accrued severance and retention costs, current portion		$ 1,408,000	$ 0
Retention Plan [Member] | Employee Severance [Member]
Restructuring Cost and Reserve [Line Items]
Maximum cash bonuses, severance payments and related benefit premiums		1,161,000
Chief Financial Officer [Member]
Restructuring Cost and Reserve [Line Items]
Compensation arrangement, cash payment		138,000
Deferred Compensation Arrangement with Individual, Severance Payable Amount		179,000
Accrued severance and retention costs, current portion		335,000
Research and Development, and Selling, General, and Administrative Expense | Retention Plan [Member] | Employee Severance [Member]
Restructuring Cost and Reserve [Line Items]
Research and development and selling, general and administrative expense		165,000
Discontinued Operations, Disposed of by Sale [Member] | Subsequent Event | Services Business [Member] | Employee Severance [Member]
Restructuring Cost and Reserve [Line Items]
Incentive payment	$ 215,000
Severance payments	$ 814,000
Discontinued Operations, Held-for-sale [Member] | Services Business [Member] | Employee Severance [Member]
Restructuring Cost and Reserve [Line Items]
Accrued severance and retention costs		999,000
Accrued severance and retention costs, current portion		908,000
Accrued severance and retention costs, net of current portion		$ 91,000

Discontinued Operations, Asse57

Discontinued Operations, Assets Held for Sale, Impairment Charges - Additional Information (Details) $ in Thousands	Jul. 21, 2015$ / h	Jul. 17, 2015USD ($)	May. 04, 2015USD ($)	Jun. 30, 2015USD ($)	Jun. 30, 2014USD ($)	Jun. 30, 2015USD ($)	Jun. 30, 2014USD ($)
Income Statement, Balance Sheet and Additional Disclosures by Disposal Groups, Including Discontinued Operations [Line Items]
Impairment charge from classification of assets as held for sale				$ (1,350)		$ (1,350)	$ 0
Services Business [Member] | Discontinued Operations, Held-for-sale [Member]
Income Statement, Balance Sheet and Additional Disclosures by Disposal Groups, Including Discontinued Operations [Line Items]
Impairment charge from classification of assets as held for sale				(1,350)	$ 0	$ (1,350)	$ 0
Period of continuing involvement						6 months
Minimum [Member] | Subsequent Event [Member] | Services Business [Member] | Discontinued Operations, Disposed of by Sale [Member]
Income Statement, Balance Sheet and Additional Disclosures by Disposal Groups, Including Discontinued Operations [Line Items]
Employees hourly rate | $ / h	100
Maximum [Member] | Subsequent Event [Member] | Services Business [Member] | Discontinued Operations, Disposed of by Sale [Member]
Income Statement, Balance Sheet and Additional Disclosures by Disposal Groups, Including Discontinued Operations [Line Items]
Employees hourly rate | $ / h	200
Research and Development Arrangement [Member] | Subsequent Event [Member]
Income Statement, Balance Sheet and Additional Disclosures by Disposal Groups, Including Discontinued Operations [Line Items]
Services agreement, term		18 months
Minimum purchase obligation		$ 3,300
Nonrecurring Adjustment [Member] | Services Business [Member] | Discontinued Operations, Held-for-sale [Member]
Income Statement, Balance Sheet and Additional Disclosures by Disposal Groups, Including Discontinued Operations [Line Items]
Impairment charge from classification of assets as held for sale			$ (1,350)	$ (1,350)

Discontinued Operations, Asse58

Discontinued Operations, Assets Held for Sale, Impairment Charges - Carrying Amounts of Assets and Liabilities of the Services Business (Details) - USD ($) $ in Thousands	Jun. 30, 2015	Dec. 31, 2014
Carrying amounts of assets included as part of discontinued operations:
Property and equipment, net	$ 3,551	$ 4,835
Impairment loss from classification of assets as held for sale	(1,350)	0
Services Business [Member] | Discontinued Operations, Held-for-sale [Member]
Carrying amounts of assets included as part of discontinued operations:
Accounts and unbilled receivables, net	1,715	1,501
Prepaid expenses and other current assets	761	289
Property and equipment, net	4,901	4,835
Other assets	59	76
Impairment loss from classification of assets as held for sale	(1,350)	0
Assets held for sale, net	6,086	6,701
Carrying amounts of liabilities included as part of discontinued operations:
Accounts payable and accrued expenses	546	681
Deferred revenue	381	445
Deferred rent	1,172	1,294
Liabilities related to assets held for sale	$ 2,099	$ 2,420

Discontinued Operations, Asse59

Discontinued Operations, Assets Held for Sale, Impairment Charges - Revenue, Expense, Gain, and Losses Attributable to Discontinued Operations (Details) - USD ($) $ in Thousands	3 Months Ended		6 Months Ended
	Jun. 30, 2015	Jun. 30, 2014	Jun. 30, 2015	Jun. 30, 2014
Income Statement, Balance Sheet and Additional Disclosures by Disposal Groups, Including Discontinued Operations [Line Items]
Impairment charge from classification of assets as held for sale	$ (1,350)		$ (1,350)	$ 0
Services Business [Member] | Discontinued Operations, Held-for-sale [Member]
Income Statement, Balance Sheet and Additional Disclosures by Disposal Groups, Including Discontinued Operations [Line Items]
Total revenue	3,617	$ 4,577	6,849	9,217
Cost of revenue	(3,599)	(4,180)	(6,830)	(8,140)
Research and development	(422)	0	(853)	0
Selling, general and administrative	(198)	0	(221)	0
Gain on insurance recovery	0	165	0	165
Severance and exit costs	(1,053)	0	(1,053)	0
Impairment charge from classification of assets as held for sale	(1,350)	0	(1,350)	0
Income (loss) from discontinued operations	$ (3,005)	$ 562	$ (3,458)	$ 1,242

Discontinued Operations, Asse60

Discontinued Operations, Assets Held for Sale, Impairment Charges - Depreciation, Capital Expenditures, and Significant Operating and Investing Non-Cash Items Related to Discontinued Operations (Details) - USD ($) $ in Thousands	3 Months Ended		6 Months Ended
	Jun. 30, 2015	Jun. 30, 2014	Jun. 30, 2015	Jun. 30, 2014
Income Statement, Balance Sheet and Additional Disclosures by Disposal Groups, Including Discontinued Operations [Line Items]
Stock-based compensation	$ 819	$ 272	$ 1,115	$ 382
Changes in deferred rent			(122)	(56)
Services Business [Member] | Discontinued Operations, Held-for-sale [Member]
Income Statement, Balance Sheet and Additional Disclosures by Disposal Groups, Including Discontinued Operations [Line Items]
Depreciation expense			391	562
Purchases of property and equipment			(527)	(323)
Stock-based compensation			101	50
Changes in deferred rent			(122)	(56)
Equipment purchases in accounts payable and accrued expenses			$ 20	$ 6

Subsequent Events (Details)

Subsequent Events (Details)	Jul. 22, 2015USD ($)ft²	Jul. 21, 2015USD ($)$ / h	Jul. 17, 2015USD ($)	Jul. 23, 2015$ / sharesshares	Jun. 30, 2015USD ($)$ / sharesshares
Subsequent Event [Member] | Compensatory Arrangement with Executive Officer [Member] | President [Member]
Subsequent Event [Line Items]
Unvested options outstanding (in shares) | shares				183,268
Weighted average exercise price, unvested options outstanding | $ / shares				$ 9.41
Compensation arrangement, cash payment		$ 100,000
Severance payments		$ 900,000
Severance payment period		12 months
Vested options outstanding (in shares) | shares				84,613
Weighted average exercise prices, vested options | $ / shares				$ 9.61
Subsequent Event [Member] | Maximum [Member] | Compensatory Arrangement with Executive Officer [Member] | President [Member]
Subsequent Event [Line Items]
Post-employment options, exercise period		48 months
Subsequent Event [Member] | Jersey City, New Jersey [Member]
Subsequent Event [Line Items]
Area of subleased space | ft²	10,141
Base rent, per month	$ 25,000
Annual increase in base rent (percent)	3.00%
Security deposit paid	$ 74,000
Subsequent Event [Member] | Research and Development Arrangement [Member]
Subsequent Event [Line Items]
Minimum purchase obligation			$ 3,300,000
Services agreement, term			18 months
Discontinued Operations, Disposed of by Sale [Member]
Subsequent Event [Line Items]
Success fee payable					$ 500,000
Percentage of transaction consideration					4.00%
Discontinued Operations, Disposed of by Sale [Member] | Services Business [Member]
Subsequent Event [Line Items]
Options outstanding (in shares) | shares					37,517
Weighted average exercise price, options outstanding | $ / shares					$ 9.62
Unvested options outstanding (in shares) | shares					23,052
Weighted average exercise price, unvested options outstanding | $ / shares					$ 9.61
Discontinued Operations, Disposed of by Sale [Member] | Subsequent Event [Member]
Subsequent Event [Line Items]
Payment of success fee		$ 450,000
Discontinued Operations, Disposed of by Sale [Member] | Subsequent Event [Member] | Services Business [Member]
Subsequent Event [Line Items]
Sale of Services Business, aggregate purchase price		3,875,000
Working capital adjustment		824,000
Consideration payable held In escrow		$ 500,000
Consideration payable held in escrow, period		12 months
Sale of Services Business aggregate purchase price, net at closing		$ 2,549,000
Post-employment options, exercise period		48 months
Discontinued Operations, Disposed of by Sale [Member] | Subsequent Event [Member] | Services Business [Member] | Minimum [Member]
Subsequent Event [Line Items]
Employees hourly rate | $ / h		100
Discontinued Operations, Disposed of by Sale [Member] | Subsequent Event [Member] | Services Business [Member] | Maximum [Member]
Subsequent Event [Line Items]
Employees hourly rate | $ / h		200
Employee Severance [Member] | Discontinued Operations, Disposed of by Sale [Member] | Subsequent Event [Member] | Services Business [Member]
Subsequent Event [Line Items]
Incentive payment		$ 215,000
Severance payments		$ 814,000